[User]
<|image|>Parse the following content of the photo in markdown code: <md> | SOC | Order |
 | --- | --- |
 | Infections and infestations | 1 |
 | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2 |
 | Blood and lymphatic system disorders | 3 |
 | Immune system disorders | 4 |
 | Endocrine disorders | 5 |
 | Metabolism and nutrition disorders | 6 |
 | Psychiatric disorders | 7 |
 | Nervous system disorders | 8 |
 | Eye disorders | 9 |
 | Ear and labyrinth disorders | 10 |
 | Cardiac disorders | 11 |
 | Vascular disorders | 12 |
 | Respiratory, thoracic and mediastinal disorders | 13 |
 | Gastrointestinal disorders | 14 |
 | Hepatobiliary disorders | 15 |
 | Skin and subcutaneous tissue disorders | 16 |
 | Musculoskeletal and connective tissue disorders | 17 |
 | Renal and urinary disorders | 18 |
 | Pregnancy, puerperium and perinatal conditions | 19 |
 | Reproductive system and breast disorders | 20 |
 | Congenital, familial and genetic disorders | 21 |
 | General

[Assistant]
disorders and administration site conditions | 22 |
 | Investigations | 23 |
 | Injury, poisoning and procedural complications | 24 |
 | Surgical and medical procedures | 25 |
 | Social circumstances | 26 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | Upregulated genes | Downregulated genes |
 | --- | --- |
 | (1) Nuclear factor (Nf-116)(2) Epidermal keratin type II(3) MEF2C transcription factor(4) Metalloproteinase(5) Tyrosine phosphatases CIP 2(6) Transforming growth factor beta binding protein(7) Mitogen inducible gene 2(8) Oncofetal antigen 5T4 | (1) Epidermal keratin types 1, 13, 15, and 16(2) Transforming growth factor beta 3 receptor(3) Differentiation dependent A4 protein(4) Ribosomal proteins L3, L8, L28, L31, and L35(5) ARF

[Assistant] activated phosphatidylcholine-specific phospholipase D1a(6) Zinc finger protein(7) DNA binding protein FKHL 15 (8) PRAD1 | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> |  |  | Group A | Group B |
 | --- | --- | --- | --- |
 | Age |  | 7-21 years | 18 months-19 years |
 | Genetic features |  |  |  |
 | Duplicate segment length |  | 107.5 Kb-700 Kb | 0.29 Kb-16.6 Mb (for two cases the size is unknown but cytogenetic visible) |
 | Inheritance | de novo | 4 | 8 |
 |  | Maternal | 5 | 0 |
 |  | Unknown | 0 | 1 |
 | XCI | Random | 6 | 2 |
 |  | Skewed | 3 | 1 |
 |  | Unknown | 0 | 6 |
 | Clinical features |  |  |  |
 | Abnormal general conditions |  | 5/9 (55%) | 9/9 (100%) |
 | Dysmorphic patterns |  | 3/9 (33%) | 9/9 (100%) |
 | Delayed motor development |  | 4/9 (44%) | 9/9 (100%) |
 | Abnormal language development |  | 6/9 (67%) | 9/9 (100%) |
 | Intellectual disability |  | 7/9 (78%) | 9/9 (100%) |
 | Mood and behaviour | Affected | 4/9 (44%) | 1/9 (11%) |
 |  | Unknown | 5/9 (55%) | 8/9 (88%) |
 | Social conduct | Affected | 8/9 (88%) | 0/9 (0%) |
 |  | Unknown | 1/9(11%) | 9/9 (100%) |
 | Autistic features |  | 4/9 (44%) | 0/9 (0%) |
 | Seizures |  | 1/8 (13%) | 3/9 (33%) |
 | Brain MRI | Abnormal | 0/9 (0%) | 3/9 (33%) |
 |  | Unknown | 1/9 (11%) | 6/9 (67%) | </md>


[User] <|image|>Transform the diagram into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Groups characteristic | <COLSPAN=2> Baseline | <ROWSPAN=2> p value |
 | PFD + MDD-O | KTS |
 | --- | --- | --- | --- |
 | Age (years) | 57.3 ± 12.6 | 51.7 ± 9.9 | 0.069 |
 | <ROWSPAN=2> Gender n (%) | Male 18 (76.9%) | Male 12 (57.7%) | <ROWSPAN=2> 0.139 |
 | Female 5 (23.1%) | Female 18 (42.3%) |
 | Years with diabetes | 14 ± 9.1 | 17 ± 10.4 | 0.416 |
 | Months with ulcers | 8.6 ± 2.7 | 6.5 ± 2.2 | 0.989 |
 | Smoking | 7 (26.9%) | 2 (7.7%) | 0.140 |
 | Glucose (mg/dL) | 139.1 ± 71.7 | 152.8 ± 85.7 | 0.597 |
 | HDL (mg/dL) | 31.4 ± 14.7 | 38.9 ± 11.8 | 0.840 |
 | VLDL (mg/dL) | 27.5 ± 11.6 | 42.6 ± 40.3 | 0.211 |
 | LDL (mg/dL) | 78.9 ± 13.5 | 101.7 ± 39.1 | 0.107 |
 | Creatinine clearance/24 h (mL/min) | 59.9 ± 20.9 | 74.2 ± 40.8 | 0.517 |
 | Urea (mg/dL) | 37.5 ± 24.4 | 46.0 ± 21.4 | 0.173 |
 | Creatinine (mg/dL) | 1.0 ± 0.5 | 1.6 ± 1.1 | 0.128 |
 | ALT (U/L) | 14.4 ± 5.4 | 25.2 ± 15.4 | 0.073 |
 | AST (U/L) | 16.0 ± 3.2 | 23.4 ± 15.0 | 0.404 |
 | GGT (U/L) | 37.1 ± 12.9 | 90.4 ± 14.5 | 0.973 |
 | VSG (mm/h) | 78.1 ± 39.2 | 64.2 ± 29.2 | 0.456 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | <ROWSPAN=2>  | <ROWSPAN=2>  | <COLSPAN=3> 2nd Derivative Spectra | <COLSPAN=3> PCA Loadings |
 | par | cal | pre | par | cal | pre |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=3>

[Assistant]
Sample set 1 | PLS-DA | 6 | 93.75 | 80.00 | 6 | 96.25 | 82.50 |
 | SVM | (1.7411, 0.1895) | 95.00 | 82.50 | (48.5029,0.3299) | 97.50 | 80.00 |
 | RBFNN | 28 | 100 | 97.50 | 11 | 100 | 97.50 |
 | <ROWSPAN=3> Sample set 2 | PLS-DA | 7 | 95.00 | 95.00 | 9 | 98.70 | 92.50 |
 | SVM | (3.0314,5.2780) | 97.50 | 82.50 | (5.2780,3.0314) | 98.75 | 87.50 |
 | RBFNN | 31 | 100 | 92.50 | 16 | 100 | 95.00 | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> |  | Health centre | 1st level referral hospital | Total |
 | --- | --- | --- | --- |
 | Operating budget/inhabitant/year | $6.05 | $11.86 | $17.91 |
 | Utilization rate (cases/inhabitant/year)

[Assistant]
| 0.4 | 0.15 | N/A |
 | No. of activities included | 98 | 117 | 215 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | Country | Participating hospital | Type of Hospital | Total no. of beds | No. of beds for general medicine | No. of beds for paediatrics | No. of beds for geriatrics | No. of ICU beds |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=6> Spain |  |  |  |  |  |  |  |
 | General CS | General | 580 | 437 | 79 | 0 | 58 |
 | La Plana | General | 251 | 100 | 19 | 0 | 9 |
 | Pesset | General | 540 | 211 | 41 | 0 | 16 |
 | San Juan | General | 350 | 230 | 37 | 0 | 13 |
 | Elda | General | 514 | 410 | 30 | 0 | 13 |
 | <ROWSPAN=6> France |  |  |  |  |  |  |  |
 | Cochin | - | 1074 | - | - | - | - |
 | Bichat | University hospital | 1000 | 954 | 0 | 20 | 24 |
 | Limoges | - | 858 | - | - | - | - |
 | Montpellier | - | 3000 | - | - | - | - |
 | Lyon | University hospital/tertiary care | 683 | 603 | 0 | 64 | 53 |
 | <ROWSPAN=2> Moscow |  |  |  |  |  |  |  |
 | Hospital #1 | Infectious diseases | 1000 | 506 | 231 | 0 | 12 |
 | <ROWSPAN=4> St. Petersburg |  |  |  |  |  |  |  |
 | Hospital #30 | Infectious diseases | 1200 | 1175 | 0 | - | 25 |
 | Hospital #5 | Children's infectious diseases | 650 | 0 | 635 | 0 | 15 |
 | Hospital #4 | Children's city hospital | 360 | 0 | 345 | 0 | 15 |
 | <ROWSPAN=8> Turkey |  |  |  |  |  |  |  |
 | Hacettepe Univ. Hospital | - | 1200 | 156 | 228 | - | 60 |
 | Gazi Univ. Hospital | - | 1150 | - | - | - | - |
 | Trakya Univ. Hospital | University hospital | 1042 | 951 | 72 | 0 | 50 |
 | Istanbul Univ. Cerrahpaşa Hospital | University hospital | - | 36 | 60 | 0 | 30 |
 | Uludağ Univ. Hospital | - | 1000 | 800 | 112 | 0 | 87 |
 | Dr. Siyami Ersek Hospital | - | - | - | - | - | - |
 | Kartal Research Hospital | Research and education Hospital | 880 | 750 | 90 | 0 | 41 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | Variable | Mean | Std.Dev. | N* | R*** | P**** | Remark |
 | --- | ---

[Assistant]
| --- | --- | --- | --- | --- |
 | Perception of abstinence-onlysexual education on | 31.2350 | 3.5843 | 2000 | -0.122** | 0.000 | Sig. |
 | Religion | 01.0800 | 0.3500 | <COLSPAN=4>  | </md>


[User] <|image|>Convert the image into Markdown language.

[Assistant]
<md> | Drug | Dose | Source | China | India | Russia | Zambia |
 | --- | --- | --- | --- | --- | --- | --- |
 | ASA | 500 mg | <ROWSPAN=2> International drug price indicator guide | $ 0.004 | $ 0.004 | $ 0.004 | $ 0.004 |
 | Propranolol | 160 mg | $ 0.005 | $ 0.005 | $ 0.005 | $ 0.005 |
 | Amitriptyline | 100 mg |  | $ 0.006 | $ 0.006 | $ 0.006 | $ 0.006 |
 | Topiramate | 100 mg |  | $ 0.13 | $ 0.03 | $ 0.12 | $ 0.133 |
 | Sumatriptan | 50 mg | IMS database | $ 0.81 | $ 0.11 | $ 1.07 | $ 0.66 |
 | Almotriptan | 12.5 mg |  | $ 5.19 | $ 5.19 | $ 5.19 | $ 5.19 | </md>


[User] <|image|>Transform the table into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> All GCRtypesa | <COLSPAN=2> CAN1/LYP1/ALP1translocationsb |
 | Relevant genotype | Rate | 95% CI | Rate | Frequency |
 | --- | --- | --- | --- | --- |
 | wildtype | 1.1 | < 1-6.2 | ND | ND |
 | rad51a | < 8 | < 7-15 | ND | ND |
 | rad52 | 138 | 16-267 | ND | ND |
 | rad59 | 24 | 13-50 | ND | ND |
 | sgs1 a | 220 | 144-276 | < 7.3 | 0/30 |
 | mec3 a | 46 | 18-75 | < 1.5 | 0/30 |
 | sgs1 rad59 | 126 | 107-300 | ND | ND |
 | sgs1 rad59 rad51 | 118 | 49-154 | ND | ND |
 | sgs1 mec3 a | 1297 | 1120-2030 | 173 | 20/150 |
 | sgs1 mec3 rad51 a | 1491 | NDc | 198 | 4/30 |
 | sgs1 mec3 rad52 a | 3168 | NDc | < 23 | 0/136 |
 | sgs1 mec3 rad59 | 2476 | 1595-3187 | 16 | 1/158 |
 | sgs1 mec3 rad59 rad51 | 1124 | 734-1460 | 7 | 1/168 | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> | <ROWSPAN=3> Neighborhood Land-Use Mix and Intensity | <COLSPAN=2> Outdoor Walking Levels |
 | Low-Deprivation Areas | High-Deprivation Areas |
 | B (SE) | B (SE) |
 | --- | --- | --- |
 | Land-use mix | 0.47 (0.22) * | −0.30 (0.25) |
 | Intensity of social infrastructure | 0.11 (0.14) | −0.27 (0.25) | </md>


[User]
<|image|>What are the following image content in markdown style: <md> |  | Physical health | Psychological health | Social relationships | Environmental health |
 | --- | --- | --- | --- | --- |
 | Bodily pain | 0.57 | 0.19 | 0.10 | 0.31 |
 | General

[Assistant]
health | 0.64 | 0.43 | 0.21 | 0.42 |
 | Vitality | 0.65 | 0.58 | 0.29 | 0.47 |
 | Physical functioning | 0.47 | 0.38 | 0.21 | 0.33 |
 | Role physical | 0.55 | 0.32 | 0.18 | 0.33 |
 | Mental health | 0.50 | 0.56 | 0.27 | 0.38 |
 | Role emotional | 0.52 | 0.52 | 0.08 | 0.46 |
 | Social functioning | 0.67 | 0.49 | 0.33 | 0.47 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Stage | Definition |
 | --- | --- |
 | I | tumor confined to gastrointestinal tract |
 | II |

[Assistant]
tumor extending into abdomen from primary site |
 | II1 | local nodal involvement (perigastric) |
 | II2 | distal nodal involvement (para-aortic or paracaval) |
 | IIE | penetration of serosa to involve adjacent organs |
 | IV | disseminated disease or supradiaphragmatic nodal involvement | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | <ROWSPAN=2> Primary Healthcare Centersa | <COLSPAN=5> Prescribing Indicators |
 | Average number of medicines prescribed per patient encounter | Percent medicines prescribed by generic name | Percent encounters with an antibiotic prescribed | Percent encounters with an injection prescribed | Percent medicines prescribed from essential medicines list |
 | --- | --- | --- | --- | --- | --- |
 | 1 | 3.4 (1.4) | 81.2 | 64.0 | 38.0 | 98.5 |
 | 2 | 3.6 (1.5) | 85.1 | 63.0 | 32.0 | 87.6 |
 | 3 | 3.4 (1.3) | 83.0 | 87.0 | 21.0 | 89.2 |
 | 4 | 3.2 (3.1) | 43.7 | 40.0 | 18.0 | 90.7 |
 | 5 | 3.2 (1.4) | 88.5 | 56.0 | 30.0 | 100 |
 | 6 | 1.9 (1.0) | 50.0 | 31.0 | 25.0 | 100 |
 | 7 | 5.0 (2.3) | 60.0 | 30.0 | 9.0 | 80.5 |
 | 8

[Assistant]
| 4.3 (2.4) | 76.0 | 28.0 | 28.0 | 100 |
 | 9 | 2.9 (0.7) | 66.7 | 29.0 | 43.0 | 100 |
 | 10 | 3.4 (1.1) | 82.0 | 61.0 | 27.0 | 87.9 |
 | Mean (SD) | 3.4 (0.8) | 71.6 (15.7) | 48.9 (20.2) | 27.1 (9.8) | 93.4 (7.1) |
 | ANOVA | p < .0005 | p < .0005 | p < .0005 | p < .0005 | p < .0005 | </md>


[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> | Plant genera | Cadmium (μg/g) | Copper (μg/g) | Lead (μg/g) | Zinc (μg/g) |
 | --- | --- | --- | --- | --- |
 | Ceratophyllum | 3.52±2.08 | 22.71±21.08 | 20.06±8.68 | 104.2±22.80 |
 | Potamogeton | 1.42±1.38 | 10.75±5.18 | 12.26±16.19 | 41.60±6.10 | </md>


[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> | Dependent variable | Independent variables | Regression coefficients | P* |
 | --- | --- | --- | --- |
 | EE† | Global job satisfaction | -0.22 | 0.03 |
 | <ROWSPAN=4>  | Trainees |  |  |
 | Global work stress = 30 points | -6.84 |  |
 | Global work stress = 64 points | 1.86 | 0.003 |
 | Global work stress = 98 points | 10.56 |  |
 | <ROWSPAN=4> DP‡ | Trainees |  |  |
 | Global work stress = 30 points | -8.17 |  |
 | Global work stress = 64 points | -7.30 | 0.002 |
 | Global work stress = 98 points | -6.44 |  |
 | <ROWSPAN=4> PA§ | Living alone (reference) | 1 |  |
 | First-degree relatives | -0.43 | 0.76 |
 | Second-degree relatives | -10.26 | <0.001 |
 | Both | -0.75 | 0.74 | </md>


[User] <|image|>Interpret the photo as Markdown format.

[Assistant]
<md> | Region | Peak t | x | y | z | k |
 | --- | --- | --- | --- | --- | --- |
 | R mid temporal gyrus | 5.14 | 48 | −42 | 3 | 55 |
 | R orbital superior frontal gyrus | 5.01 | 15 | 54 | −15 | 42 |
 | L inferior/mid frontal gyrus | 4.47 | −36 | 24 | 18 | 43 |
 | R mid cingulate gyrus | 4.17 | 6 | −21 | 27 | 36 |
 | L caudate | 3.99 | −9 | 9 | 9 | 29 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | <ROWSPAN=2> Compounds | <COLSPAN=7> Minimum Inhibitory Concentration (MIC) in μg/mL |
 | S.typhii | K. pneumoniae | E.coli | P. aeruginosa | S.aureus | β-H. streptococcus | M.luteus |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | 17 | 100 | 100 | 200 | 100 | 50 | 50 | 6.25 |
 | 18 | 200 | 100 | - | 100 | 12.5 | 6.25 | 12.5 |
 | 19 | 6.25 | 6.25 | 25 | 6.25 | 12.5 | 6.25 | 25 |
 | 20 | 200 | - | 200 | 200 | 6.25 | 12.5 | 12.5 |
 | 21 | 12.5 | 25 | 6.25 | 12.5 | 12.5 | 25 | 6.25 |

[Assistant]
| 22 | 25 | 25 | 100 | 6.25 | 100 | 25 | 50 |
 | 23 | 25 | 12.5 | 50 | 6.25 | 6.25 | 25 | 12.5 |
 | 24 | 25 | 12.5 | 25 | 25 | 12.5 | 6.25 | 50 |
 | Ciprofloxacin | 25 | 25 | 50 | 25 | 25 | 50 | 25 | </md>


[User] <|image|>Interpret the illustration as Markdown format.

[Assistant]
<md> |  | No. | % |
 | --- | --- | --- |
 | Patients |  |  |
 | Treated | 39 | 100.0 |
 | Evaluable for response | 36 | 92.3 |
 | Age |  |  |
 | Median (years) | 51.3 |  |
 | Range | 41.2 – 64.1 |  |
 | ECOG performance status |  |  |
 | 0 | 3 | 7.7 |
 | 1 | 27 | 69.2 |
 | 2 | 9 | 23.1 |
 | Site(s) of metastatic lesion(s)* |  |  |
 | Lung | 27 | 69.2 |
 | Liver | 9 | 23.1 |
 | Lymph node | 15 | 38.5 |
 | Soft tissue | 3 | 7.7 |
 | Bone | 24 | 61.5 |
 | Brain | 3 | 7.7 |
 | Response to prior anthracyclines |  |  |
 | Primary resistant | 24 | 61.5 |
 | Secondary resistant | 15 | 38.5 |
 | Interval from the cessation of last chemotherapy |  |  |
 | Median (months) | 4.1 |  |
 | Range | 1.0 – 11.2 |  |
 | No. of prior chemotherapy regimens |  |  |
 | Hormonal therapy (total) | 20 | 51.3 |
 | 1 | 9 | 23.1 |
 | 2 | 21 | 53.8 |
 | 3 or more | 9 | 23.1 |
 | Characteristics of prior chemotherapy† |  |  |
 | CMF | 24 |  |
 | CAF | 15 |  |
 | FEC | 9 |  |
 | VE | 21 |  |
 | High-dose therapy with stem cell rescue | 6 |  |
 | AT | 3 |  | </md>


[User] <|image|>Translate the figure into Markdown format.

[Assistant]
<md> | Arabidopsis | Ref | Rice | Ref | Barley | Ref | Wheat | Ref |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | AG | (1) | OsMADS53‐58 | (2) |  |  |  |  |
 | EMS1/TPD1 | (3,4,5) | MSP1/OsTDL1 | (6, 7) |  |  |  |  |
 | DYT1 | (8,9) | UDT1 | (10) |  |  |  |  |
 | TDF | (11) |  |  |  |  |  |  |
 | AMS | (12,13,14) | TDR | (13,15,16) |  |  |  |  |
 | MYB103/80 | (17) | OsMYB103/80 | (18) |  |  |  |  |
 | MS1 | (19,20,21) | PTC1 | (16) | HvMS1 | (22) |  |  |
 | MYB33‐65 | (23) | OsGAMYB | (24) | HvGAMYB | (25) |  |  |
 | MS2 | (26) | OsDPW | (27) |  |  |  |  |
 | DEX1 | (28) | OsDEX1 | (28) | HvDEX1 | (28) |  |  |
 |  |  | RAFTIN | (29) |  |  | RAFTIN | (29) | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> |  | Anosmics | Hyposmics | Normosmics | Total |
 | --- | --- | --- | --- | --- |
 | Normosmic sample | 0 | 23 |

[Assistant]
384 | 407 |
 | Anosmic sample | 16 | 1 | 0 | 17 | </md>


[User] <|image|>Translate the figure into Markdown format.

[Assistant]
<md> | Items on CTCS-SP | CGI-I |
 | --- | --- |
 | 1. Agenda setting | −.35 |
 | 2. Dealing with questions/objections/problems | −.43 |
 | 3. Clarity of communication | −.46 |
 | 4. Pacing and efficient use of time | −.65** |
 | 5. Interpersonal effectiveness | −.51** |
 | 6. Resource activation | −.61** |
 | 7. Reviewing social-phobia questionnaires and other measures | −.21 |
 | 8. Reviewing previously set homework | −.31 |
 | 9. Use of feedback and summaries | −.22 |
 | 10. Guided discovery | −.48 |
 | 11. Focus on social-phobia-related cognitions, self-focused attention, safety behaviors, and biased imagery | −.49* |
 | 12. Rationale | −.36 |
 | 13. Selection of appropriate strategies for change in social-phobia-related cognition and maintaining factors (including selection of behavioral experiments and other experiential exercises). | −.59** |
 | 14. Appropriate implementation of techniques for change in social-phobia-related cognition and maintaining factors (including selection of behavioral experiments and other experimental exercises). | −.56** |
 | 15. Integration of discussion and experiential techniques | −.34 |
 | 16. Setting homework | −.23 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Disorder | No. of clinically evaluated individuals | No. of cases confirmed by genetic testing | % of positive test (2011) | % of positive test (2007) | Trend from last survey |
 | --- | --- | --- | --- | --- | --- |
 | Williams Syndrome | 610 | 149 | 24 | 3 |

[Assistant]
++ |
 | DiGeorge/Velocardiofacial Syndrome | 2260 | 736 | 33 | 3 | ++ |
 | Fragile X Syndrome | 8240 | 353 | 4 | 4 | = |
 | Achondroplasia | 186 | 84 | 45 | 36 | + |
 | Noonan Syndrome | 968 | 267 | 28 | NE |  |
 | Angelman Syndrome | 713 | 49 | 7 | 9 | - |
 | Prader-Willi Syndrome | 927 | 78 | 8 | 18 | - - |
 | Ankylosing spondylitis | 2826 | 418 | 15 | NE |  |
 | Celiac diseases | 6748 | 3488 | 52 | NE |  | </md>


[User] <|image|>Express the illustration as Markdown code.

[Assistant]
<md> |  | 21 days | 35 days | 50 days | 100 days |
 | --- | --- | --- | --- | --- |
 | Uterine weight (mg) |  |  |  |  |
 | Control | 30.0 ± 1.4 | 167 ± 27 | 288 ± 17 | 409 ± 20 |
 | BBP | 36.0 ± 2.1 | 207 ± 16 | 319 ± 24 | 429 ± 19 |
 | Uterine weight/BW (mg/g) |  |  |  |  |
 | Control | 0.51 ± 0.03 | 1.27 ± 0.20 | 1.48 ± 0.08 | 1.31 ± 0.07 |
 | BBP | 0.65 ± 0.04* | 1.56 ± 0.13 | 1.65 ± 0.10 | 1.39 ± 0.04 |
 | Development of the mammary gland |  |  |  |  |
 | Number of TEB |  |  |  |  |
 | Control | 39.5 ± 2.32 | 30.4 ± 5.22 | 18.3 ± 3.71 | 0.22 ± 0.22 |
 | BBP | 40.0 ± 4.68 | 30.2 ± 5.78 | 22.7 ± 3.16 | 0.40 ± 0.40 |
 | Number of TD |  |  |  |  |
 | Control | 24.5 ± 1.65 | 38.2 ± 4.17 | 41.1 ± 3.40 | 57.3 ± 5.21 |
 | BBP | 25.9 ± 2.52 | 33.5 ± 4.08 | 46.6 ± 7.31 | 61.8 ± 5.41 |
 | Number of AB |  |  |  |  |
 | Control | 8.0 ± 1.87 | 14.9 ± 1.08 | 10.1 ± 2.04 | 0.2 ± 0.22 |
 | BBP | 5.7 ± 1.20 | 13.7 ± 1.65 | 8.9 ± 1.05 | 0.2 ± 0.20 |
 | Number of Lob1 |  |  |  |  |
 | Control | 0 | 30.1 ± 4.58 | 43.4 ± 5.74 | 42.7 ± 6.41 |
 | BBP | 0 | 39.0 ± 7.29 | 42.9 ± 4.43 | 46.2 ± 8.64 | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | <COLSPAN=4> Transcriptional activation |
 | --- | --- | --- | --- |
 | Gene function | Gene Name | Effect of ICRF-187 | Effect of m-AMSA |
 | DNA damage | RNR3 | 3.2 | 4.0 |
 |  | HUG1 | 3.1 | 5.0 |
 |  | RAD51 | 1.9 | 2.0 |
 |  | RAD54 | 1.7 | 1.6 |
 |  | RNR2 | 1.5 | 1.8 |
 | Membrane transport | PDR12 | 2.4 | 1.0 |
 |  | PDR15 | 2.0 | 1.0 |
 | Stress response | HSP12 | 2.8 | 1.6 |
 |  | HSP26 | 1.7 | 1.8 |
 |  | WSC4 |

[Assistant]
1.6 | 1.3 |
 |  | XBP1 | 1.6 | 1.5 |
 |  | HSP42 | 1.5 | 1.5 |
 | Others | SWI1 | 1.6 | 1.1 |
 | Transcriptional repression |  |  |  |
 | Others | SNZ1 | 0.6 | 1.1 |
 |  | PCL9 | 0.7 | 0.6 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> |  | Cancellous Bone | Cartilage | Cortical Bone | Fat | Mucosa | Muscle | Nerve | Salivary Gland |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Cartilage | 1.00 |  |  |  |  |  |  |  |
 | Cortical bone | 1.00 | 1.00 |  |  |  |  |  |  |
 | Fat | 1.00 | 1.00 | 1.00 |  |  |  |  |

[Assistant]
|
 | Mucosa | 1.00 | 0.95 | 0.99 | 0.99 |  |  |  |  |
 | Muscle | 0.99 | 1.00 | 0.98 | 1.00 | 1.00 |  |  |  |
 | Nerve | 1.00 | 1.00 | 0.98 | 0.96 | 0.98 | 1.00 |  |  |
 | Salivary gland | 1.00 | 1.00 | 1.00 | 1.00 | 0.94 | 0.94 | 1.00 |  |
 | Skin | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | </md>


[User] <|image|>Translate the picture into Markdown format.

[Assistant]
<md> | Ingredient | "High+Fe" Diet | "High" Diet | "Low+Fe" Diet | "Low" Diet |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> g/Kgdiet (by formulation) |
 | High-Fe bioavailability Maize (21 μg Fe/g) | 750 | 750 | - | - |
 | Low-Fe bioavailability Maize (20 μg Fe/g) | - | - | 750 | 750 |
 | Dry skim milk | 100 | 100 | 100 | 100 |
 | DL-Methionine | 2.5 | 2.5 | 2.5 | 2.5 |
 | Corn oil | 30 | 30 | 30 | 30 |
 | Corn starch | 46.50 | 46.75 | 46.50 | 46.75 |
 | Choline Chloride | 0.75 | 0.75 | 0.75 | 0.75 |
 | Vit/Min1 (no Fe) | 70 | 70 | 70 | 70 |
 | Ferric citrate | 0.25 | - | 0.25 | - |
 | Total | 1000 | 1000 | 1000 | 1000 |
 | <COLSPAN=5> Concentrations of selected components means±SEM, n=10 (by analysis)4 |
 | Fe, μgFe/g diet2 | 65.3±0.9a | 24.5±1.0b | 66.1±2.4a | 23.6±0.2b |
 | Phytate, μmol/g diet3 | 10.2 ± 0.2a | 10.1 ±0.2a | 10.1 ± 0.2a | 10.0 ±0.2a | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | <ROWSPAN=2>  | URS+ | URS- | <ROWSPAN=2> P-value |
 | Mean±SD/ (N,%) | Mean±SD/ (N,%) |
 | --- | --- | --- | --- |
 |  | 3,079 (53.9) | 2,634 (46.1) |  |
 | <COLSPAN=4> Gender |
 | Male

[Assistant]
(N, %) | 1,346 (43.72%) | 1,126 (42.75%) | 0.462 |
 | Female (N, %) | 1,733 (56.28%) | 1,508 (57.25%) |  |
 | Age (Mean±SD) | 67.79 (±10.68) | 67.63 (±11.15) | 0.599 |
 | <COLSPAN=4> Age (N,%) |
 | <65 years | 1,092 (35.47%) | 952 (36.14%) | 0.491 |
 | 65-74 years | 1,150 (37.35%) | 944 (35.84%) |  |
 | >74 years | 837 (27.18%) | 738 (28.02%) |  |
 | <COLSPAN=4> CCI score (N,%) |
 | 0 | 272 (8.83%) | 341 (12.95%) | <0.001* |
 | 1 | 217 (7.05%) | 245 (9.30%) |  |
 | ≧2 | 2,590 (84.12%) | 2,048 (77.75%) |  |
 | <COLSPAN=4> Comorbidity |
 | <COLSPAN=4> Hypertension |
 | No | 1,443 (46.87%) | 1,300 (49.35%) | 0.061 |
 | Yes | 1,636 (53.13%) | 1,334 (50.65%) |  |
 | <COLSPAN=4> Hyperlipidemia |
 | No | 2,371 (77.01%) | 2,138 (81.17%) | <0.001* |
 | Yes | 708 (22.99%) | 496 (18.83%) |  |
 | <COLSPAN=4> Diabetes |
 | No | 2,345 (76.16%) | 2,054 (77.98%) | 0.103 |
 | Yes | 734 (23.84%) | 580 (22.02%) |  |
 | <COLSPAN=4> ESRD |
 | No | 2,490 (80.87%) | 2,072 (78.66%) | 0.038* |
 | Yes | 589 (19.13%) | 562 (21.34%) |  | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> | <COLSPAN=2> Participant ID |
 | --- | --- |
 | 111Age 26–305th pregnancy | I know the nurses’ job and especially the doctor’s job is not an easy task. They try their very best to assist pregnant mothers. A job well done to them and do continue your usual jobs. Also allow sufficient time for prenatal care visits. Thank you! |
 | 174Age 20 or younger1st pregnancy | The prenatal care program has been played an important role in my life as well as other pregnant women. Keep up the good job. |
 | 233Age 26–301st pregnancy | Prenatal clinic staff is very helpful and polite. I love the nurses. Always kind. My current doc didn’t tell me about many of the things asked in this survey. Equipment needs upgrade and waiting room needs to be expanded. Doctors need to be more involved in a sense and more inclined to ask and test when needed. Also need psychological clinic for pregnant women... |
 | 213Age 26–304th pregnancy | My main concern would be the availability of doctors and waiting area. The waiting area needs more room and space. |
 | 147Age 21–251st pregnancy | I think that the nurses are very kind. My only problem is the waiting area, the waiting time to see the doctors. I am aware that they have to run errands but when setting an appointment, they should try to stick with the apt. as much as possible. I feel that regardless of how many patients are waiting to see the doctor, they should try to at least accommodate you and everything you ask. I had an experience with one of the doctors that he was rushing me with all the questions I had. I do think that the prenatal program is great and they do take care of us as far as allowing us to be seen for free. Not a lot of hospitals give those services. |
 | 257Age 31–352nd pregnancy | Prenatal care is on the average basis. Some receptionists/nurses are caring and comforting, while some are not. We need more doctors and a bigger more comfortable clinic. We need nutritionists at least at our 1st or 2nd visits to talk about nutritional eating or pregnancy diet. Nonetheless, we need a new ultrasound scanner. :) |
 | 292Age 26–304th pregnancy | The service is good but the time, the patient wait is so long.

[Assistant]
Appointment should be on time, as we have things to do. Time is important not really in prenatal but in every section in this hospital. |
 | 229Age 31–351st pregnancy | The major issue I have with the clinic is the amount of time it takes to see the Doctor. It takes 2 to 3 h to see a Doctor, regardless of the time of your appointment. If this can be addressed and new procedures for check in are made, I would be happy with the service. |
 | 218Age 21–251st pregnancy | The service provided by the doctors and nurses at the clinic is outstanding but the only problem is that the clinic is too small and the waiting room does not have enough space for all pregnant women coming to the clinic for their prenatal visits. |
 | 101Age 26–302nd pregnancy | It’ll be nice if we are provided with information on prenatal clinics and pregnancy especially some women are new at it. Although this is my second baby there are still more information I would like to know in order for me to be prepared for my future pregnancies such as weight loss/gain before, during, and after pregnancy. | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | Question | Answer | Exposure rule |
 | --- | --- | --- |
 | Did you chop down trees? | Yes | Probable exposure |
 | → How did you usually chop down trees? | Chainsaw | High level |

[Assistant] |  | Hand saw | Medium level | </md>


[User] <|image|>Convert the image into Markdown language.

[Assistant]
<md> |  | β | 95% CI | p-value |
 | --- | --- | --- | --- |
 | Depression | 3.31 | 2.70-3.93 | <0.001 |
 | Urinary tract infection with or without ongoing treatment | 1.07 | 0.22-1.91 | 0.014 |
 | Constipation | 0.74 | 0.13-1.36 | 0.018 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> |  | Hypertensive (40) | Normotensive (40) | Insulin resistant (62) | Insulin sensitive (18) |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Weight (Kg) | 76.36 (22.65) | 76.98 (23.86) | 80.1 (21.29) | 64.86 (25.81) |
 | <COLSPAN=2> t = −0.12, p = 0.91 | <COLSPAN=2> t = 2.55, p = 0.013* |
 | <ROWSPAN=2> WC (cm) | 102.28 (14.53) | 98.53 (17.21) | 102.63 (15.09) | 92.72 (16.8) |
 | <COLSPAN=2> t = 1.05, p = 0.30 | <COLSPAN=2> t = 2.39, p = 0.019* |
 | <ROWSPAN=2> Hip (cm) | 110.23 (15.92) | 111.78 (16.16) | 113.53 (15.14) | 102.28 (16.01) |
 | <COLSPAN=2> t = −0.43, p = 0.67 | <COLSPAN=2> t = 2.74, p = 0.008* |
 |

[Assistant]
<ROWSPAN=2> BMI (Kg/m2) | 31.55 (8.18) | 31.72 (9.67) | 32.96 (8.42) | 27.07 (9.23) |
 | <COLSPAN=2> t = −0.09, p = 0.93 | <COLSPAN=2> t = 2.56, p = 0.013* |
 | <ROWSPAN=2> WHR | 0.93 (0.09) | 0.88 (0.07) | 0.905 (0.085) | 0.908 (0.089) |
 | <COLSPAN=2> t = 2.83, p = 0.01* | <COLSPAN=2> t = −0.11, p = 0.91 |
 | <ROWSPAN=2> WHtR | 0.66 (0.09) | 0.63 (0.11) | 0.66 (0.1) | 0.6 (0.1) |
 | <COLSPAN=2> t = 1.21, p = 0.23 | <COLSPAN=2> t = 2.17, p = 0.033* |
 | <ROWSPAN=2> C-index | 1.36 (0.10) | 1.30 (0.10) | 1.324 (0.105) | 1.336 (0.104) |
 | <COLSPAN=2> t = 2.43, p = 0.02* | <COLSPAN=2> t = −0.38, p = 0.708 | </md>


[User]
<|image|>Parse the illustration content behind with markdown code: <md> | Source of variation | df | SS | VC | PV | Fixation indices |
 | --- | --- | --- | --- | --- | --- |
 | Among subgroups | 2 | 41.934 | 0.40244 Va | 12.31 | FSC = 0.01491** |
 |

[Assistant]
Among populations within subgroups | 16 | 56.715 | 0.04273 Vb | 1.31 | FST = 0.13620 |
 | Within populations | 294 | 830.102 | 2.82348 Vc | 86.38 | FCT = 0.12312 |
 | Total | 312 | 928.751 | 3.26865 |  |  | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | Matrix Identifier | Cor.|PMBEC | Cor.|BLOSUM62 | Description |
 | --- | --- | --- | --- |
 | HENS920104

[Assistant]
| 0.64 | 0.96 | BLOSUM50 [1] |
 | KANM000101 | 0.63 | 0.96 | OPTIMA [23] |
 | JOHM930101 | 0.63 | 0.87 | Johnson & Overington [24] |
 | HENS920102 | 0.62 | 1.00 | BLOSUM62 [1] |
 | KOSJ950115 | 0.62 | 0.81 | Koshi & Goldstein [25] |
 | HENS920103 | 0.61 | 0.97 | BLOSUM80 [1] |
 | OVEJ920105 | 0.61 | 0.69 | Overington et al. [26] |
 | BENS940103 | 0.61 | 0.93 | Benner et al. [27] |
 | VOGG950101 | 0.61 | 0.93 | Vogt et al. [28] |
 | GONG920101 | 0.61 | 0.93 | Gonnet et al. [29] | </md>


[User] <|image|>Express the picture as Markdown code.

[Assistant]
<md> | Poisson model main effect | Enteric infection (any pathogen) RR (95% CI) | Bacterial infection RR (95% CI) | Protozoal infection RR (95% CI) | Viral infection RR (95% CI) | Diarrhoea RR (95% CI) |
 | --- | --- | --- | --- | --- | --- |
 | Household toileta | 0.91 (0.79, 1.06) | 0.87 (0.75, 1.02) | 0.64 (0.39, 1.04) | 1.12 (0.79, 1.60) | 1.00 (0.68, 1.45) |
 | Household toilet to draina | 0.93 (0.80, 1.07) | 0.90 (0.77, 1.05) | 0.74 (0.45, 1.21) | 0.89 (0.62, 1.27) | 1.05 (0.73, 1.52) |
 | Dry seasonb | 0.86 (0.69, 1.08) | 0.86 (0.67, 1.09) | 0.56 (0.28, 1.12) | 0.87 (0.50, 1.54) | 1.02 (0.64, 1.63) |
 | SW monsoonb | 0.92 (0.72, 1.16) | 0.83 (0.64, 1.07) | 0.88 (0.49, 1.57) | 1.19 (0.73, 1.92) | 1.26 (0.81, 1.97) |
 | NE monsoonb | 1.07 (0.79, 1.44) | 1.11 (0.81, 1.53) | 0.96 (0.52, 1.77) | 0.40 (0.14, 1.17) | 0.70 (0.33, 1.48) | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> | <ROWSPAN=2> Diagnostic test | Total | Iringa DC | Mufindi DC | <ROWSPAN=2> P value* |
 | Tested Positive (%) | Tested Positive (%) | Tested Positive (%) |
 | --- | --- | --- | --- | --- |
 | RDT | 1839 120 (6.5) | 1092 62 (5.7) | 747 58 (7.7) | 0.07 |
 | BS1 | 1710 50 (2.9) | 941 34 (3.6) | 769 16 (2.1) | 0.11 |
 | BS2 | 1650 42 (2.5) | 989

[Assistant]
33 (3.3) | 661 9 (1.4) | 0.025 |
 | BS-sum | 1555 34 (2.2) | 933 29 (3.1) | 622 5 (0.8) | 0.002 |
 | qPCR1 | 1506 64 (4.2) | 912 55 (6.0) | 594 9 (1.5) | <0.001 | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> |  | mainly-alpha | mainly-beta | alpha/beta | alpha+beta |
 | --- | --- | --- | --- | --- |
 | H-bonds |  |  |  |  |
 | MM-type | 0.95 | 0.83 | 0.97 | 0.96 |
 | MS-type | 0.61 | 0.49 | 0.83 | 0.79 |
 | SM-type | 0.70 | 0.39 | 0.85 | 0.81 |
 | SS-type | 0.67 | 0.41 | 0.82 | 0.81 |
 | Total | 0.93 | 0.80 | 0.97 | 0.95 |
 | Total Accessibility |  |  |  |  |
 | polar- | 0.89 | 0.89 | 0.93 | 0.94 |
 | non polar- | 0.92 | 0.90 | 0.95 | 0.92 |
 | Total | 0.95 | 0.93 | 0.96 | 0.94 |
 | Void |  |  |  |  |

[Assistant]
 | total void volumes | 0.87 | 0.9 | 0.92 | 0.91 |
 | void numbers | 0.97 | 0.91 | 0.99 | 0.97 |
 | water |  |  |  |  |
 | molecule number | 0.93 | 0.91 | 0.97 | 0.93 |
 | protein-water H-bonds | 0.8 | 0.76 | 0.71 | 0.73 |
 | protein-water H-bonds/total accessibility | 0.84 | 0.81 | 0.78 | 0.73 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | Group | Total cases | CR (n) | CR rate (%) | χ2 | P-value |
 | --- | --- | --- | --- | --- | --- |
 | Needle-free injection | 80 | 74 |

[Assistant]
92.5 | 4.066 | 0.044 |
 | External application | 80 | 65 | 81.3 |  |  | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> | Sensor | Resolution (°C) | Range (°C) | Error (°C) | Power Consumption | Area (mm2) | CMOS Technology (μm) |
 | --- | --- | --- | --- | --- | --- | --- |
 | This Work | 0.05 | 0∼90 | ±0.6 | 30 μW@10 Hz | 0.12 | 0.35 |
 | [5] | 0.5 | 0∼75 | ±1.0 | 9 μW@20 Hz | 0.4 | 0.35 |
 | [6] | 0.09 | 0∼90 | ±0.3 | 36.7 μW@2 Hz | 0.6 | 0.35 |
 | [7] | 0.3 |

[Assistant]
0∼100 | −1.6∼3 | 0.22 μW@100 Hz | 0.05 | 0.18 |
 | [8] | 0.78 | 0∼100 | ±4 # | 1.2 mW@5 kHz | 0.12 | 0.13 |
 | [9] | 0.133 | 0∼100 | −0.7∼0.6 # | 175 μW@1 kHz | NA | 0.18/0.22 | </md>


[User]
<|image|>Continue parse the photo with markdown style: <md> | Computational operation | Hidden layer 1 | Bicubic interpretation |
 | --- | --- | --- |
 | Integer addition | 15 times | 0 times |
 | Integer division | 1 time | 0 times |
 | Integer multiplications | 16 times |

[Assistant]
0 times |
 | Floating-point additions | 4.6 times | 41 times |
 | Floating-point multiplications | 0 times | 28 times | </md>


[User] <|image|>Encode the diagram in Markdown syntax.

[Assistant]
<md> |  | Temporalis muscle* | C5-C6 zygapophyseal joint* | Second metacarpal* | Tibialis anterior muscle* |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Group 1 (Rule positive, n = 89) |
 | Right side | 200.0 (179.6, 220.3) | 220.4 (174.5, 230.2) | 238.7 (216.6, 261.0) | 386.0 (341.2, 430.9) |
 | Left side | 192.0 (171.6, 212.3) | 192.4 (164.6, 220.2) | 229.2 (207.1, 251.5) | 379.7 (334.9, 424.6) |
 | <COLSPAN=5> Group 2 (Rule negative, n = 108) |
 | Right side | 238.7 (220.1, 257.4) | 253.0 (227.6, 278.5) | 281.8 (261.6, 302.0) | 464.1 (423.0, 505.2) |
 | Left side | 214.5 (195.8, 233.1) | 238.5 (213.0, 263.9) | 269.4 (248.9, 289.8) | 444.6 (403.1, 486.1) | </md>


[User] <|image|>Interpret the table as Markdown format.

[Assistant]
<md> |  | CN (n = 37) | MDD (n = 53) | T/X2 | P-value |
 | --- | --- | --- | --- | --- |
 | Age | 42.19 ± 11.49 | 39.81 ± 11.64 | 0.96 | 0.340 |
 | Gender (M/F) | 21/16 | 26/27 | 0.52 | 0.524† |
 | Education | 11.54 ± 4.07 | 9.98 ± 4.00 | 1.81 | 0.074 |
 | GM (ml) | 649.34 ± 64.16 | 622.59 ± 57.06 | 2.08 | 0.041 |
 | HAMD | 1.11 ± 1.51 | 22.69 ± 4.69 | 26.83 | <0.001 |
 | HAMA | 1.41 ± 2.08 | 18.77 ± 6.05 | 16.75 | <0.001 |
 | MGPS | 1.57 ± 0.68 | 1.55 ± 0.69 | 0.07 | 0.941 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Author | Year | Country | Type | Method | Reference | Case number (high/low) | Survival analysis | Analysis type | Follow-up months | HR availability | Quality score |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Ma et al. [40] | 2017 | China | GC | RT-PCR | GAPDH | 98 | OS | Kaplan–Meier | 60 | Indirectly | 7 |
 | Du et al. [22] | 2017 | China | PCa | RT-PCR | GAPDH | 62 | OS | Kaplan–Meier | 36 | Indirectly | 6 |
 | Xiao et al. [45] | 2017 | Ukraine | CRC | RT-PCR | GAPDH | 70 | OS | Multivariate | 100 | Indirectly | 6 |
 | Wu et al. [16] | 2017 | China | ESCC | RT-PCR | GAPDH | 64/63 | OS | Multivariate | 100 | Indirectly | 8 |
 | Chen et al. [17] | 2017 | China | CRC | RT-PCR

[Assistant]
| GAPDH | 58/57 | OS | Kaplan–Meier | 150 | Indirectly | 8 |
 | Wei et al. [21] | 2017 | China | PC | RT-PCR | GAPDH/RNU6B | 32/32 | OS | Multivariate | 30 | Indirectly | 6 |
 | Du et al. [38] | 2017 | China | Glioma | RT-PCR | GAPDH | 35/34 | OS | Multivariate | 36 | Indirectly | 6 |
 | Hu et al. [23] | 2017 | China | BC | RT-PCR | GAPDH | 32/20 | OS | Kaplan–Meier | 50 | Indirectly | 6 |
 | Kobayashi et al. [20] | 2016 | Japan | CSCC | RT-PCR | GAPDH | 24/25 | OS | Multivariate | 160 | Indirectly | 6 |
 | Chen et al. [19] | 2016 | China | GC | RT-PCR | GAPDH | 54/52 | OS | Kaplan–Meier | 120 | Indirectly | 8 |
 | Song et al. [14] | 2016 | China | NPC | RT-PCR | GAPDH | 76/32 | OS | Kaplan–Meier | 120 | Indirectly | 8 | </md>


[User] <|image|>What are the following figure content in markdown style: <md> | <COLSPAN=4> No. of mice with indicated genotype (%

[Assistant]
of total No) |
 | --- | --- | --- | --- |
 | +/+ | +/- | -/- | Total No. of mice |
 | 8 | 18 | 9 | 35 |
 | (23) | (51) | (26) | (100) | </md>


[User] <|image|>Convert the figure into Markdown language.

[Assistant]
<md> | Proposed features for internal stabilisation in thermostable proteins | Contributing factors | References |
 | --- | --- | --- |
 | Helix stabilisation | Low frequency of Cβ-branched amino acids (e.g. Val, Ile, Thr). Specific amino acids at helical ends (e.g. Pro) | [16, 17] |
 | Stabilising interactions in folded protein | Disulfide bridges;Hydrogen bonds;Hydrophobic interactions;Aromatic interactions;Ion-pair networks (charged residues);Docking of loose ends | [18–24] |
 | Stabilising interactions between domains/subunits | Oligomer formation via e.g. ion pair networks | [17, 19, 25] |
 | Dense packing | Increase core hydrophobicit;, Fill cavities.Not a generally applicable feature as shown by Karshikoff & Ladenstein [21] | [19] |
 | Stable surface-exposed amino acids | Low level of surface amino acids prone to deamidation (e.g. Gln, Asn) or oxidative degradation (e.g. Cys, Met) | [17, 24] |
 | Approaches to introduce internal thermostability in mesophilic proteins | Engineering methodology |  |
 | Reducing length of or stabilising surface loops and turns | Structure-based site directed mutagenesis.Promising results reported for:Loop deletions; Proline-stabilisation of loops;Docking of loose ends. | [17, 24] |
 | Introduce stabilising interactions | Structure-based site directed mutagenesis. Success reported for introduction of ion-pairs, disulphide bridges, while core packing and helix stabilisation usually do not result in high stability gain. | [17, 24] |
 | Activity screen of diversified library at desired temperature | Directed evolution and other random methods utilized successfully in several cases | [24, 26] |
 | Approaches to develop thermostable proteins |  |  |
 | Diversifying specificity | (Structure-based) directed evolution by e.g. oligonucleotide randomisation in active site region, successfully utilized | [27] |
 | Improving activity at selected pH values | Directed evolution | [28] |
 | Broadening temperature range for activity by introducing flexibility in active site region | (Structure-based) directed evolutionPatent by Diversa.Can be made e.g. by oligonucleotide randomisation in active site region.Saturation mutagenesis at selected positions also used. | [29] |
 | Substitution of surface-exposed amino acids to achieve long term stability | Site directed or saturation mutagenesis at selected positions to reduce Gln, Asn, Cys, Met, suggested | [16, 17] | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Variable | <COLSPAN=3> Smoking status | <COLSPAN=3> High cigarette consumption |
 | B | SE | χ2 | B | SE | χ2 |
 | --- | --- | --- | --- | --- | --- | --- |
 | Year | −.02 | .01 | 9.39⁎⁎ | .00 | .00 | 1.75 |
 | CFCS | −.02 | .01 | 7.52⁎⁎ | −.00 | .00 | −.21 |
 | Post-smoking regulation period | −.20 | .18 | 1.36 | −.04 | .02 | − 2.30⁎ |
 | CFCS × post-smoking regulation period | .00 | .00 | 1.20 | .00 | .00 | .82 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> |  | Systolic BP | Fat | Saturated fat | Cholesterol | Intake energy | Vitamin C | Dietary fiber | Sodium |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Systolic BP | 1 |  |  |  |  |  |  |  |
 | Fat | −0.002 | 1 |  |  |  |  |  |  |
 | Saturated fat | −0.04 | 0.748∗ | 1 |  |  |  |  |  |
 | Cholesterol | −0.04 | 0.066 | 0.123 | 1 |  |  |  |  |
 | Intake energy | −0.04 | 0.661∗ | 0.567∗ | 0.046 | 1 |  |  |  |
 | Vitamin C | −0.02 | 0.06 | 0.008 | −0.07 | 0.257∗ | 1 |  |  |
 | Dietary fiber | −0.006

[Assistant]
| 0.121 | 0.031 | 0.006 | 0.438∗ | 0.534∗ | 1 |  |
 | Sodium | 0.847∗ | 0.06 | 0.019 | −0.07 | 0.159∗ | 0.03 | 0.07 | 1 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> |  | <COLSPAN=7> Number of participants by role |  |
 | Development stage | Multidisciplinary healthcare practitioner | Healthcare or project manager | patient or carer | Researcher or academic | Student/fellow | Data analyst | Other | Total |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | I. Scoping review | — | — | — | — | — | — | — | 0 |
 | II. Group discussions | 5 | 9 | 0 |

[Assistant]
3 | — | 3 | 2 | 22 |
 | III. Stakeholder engagement event | 22 | 12 | 10 | 8 | 7 | 1 | 7 | 74 |
 | IV. Interviews | 6 | 3 | 1 | — | — | — | 2 | 12 |
 | V. Small-scale testing | 6 | 1 | 3 | 1 | 11 | — | — | 11 |
 | VI. Piloting | 30 | 16 | 17 | 6 | 8 | — | 20 | 106 | </md>


[User] <|image|>Transform the figure into Markdown format.

[Assistant]
<md> | Woylie ID number | Trypanosome species | April 2011 | June 2011 | July | Nov | Dec | March | April |
 |  |  |  |  | 2011 | 2011 | 2011 | 2012 | 2012 |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | WC2741 | T. vegrandis sp. nov. | + | + | + | + | + | + | + |
 | WC2830 | T. vegrandis sp. nov. | - | - | - | - | - | - | - |
 | WC2842 | T. vegrandis sp. nov. | - | - | - | - | - |  | - |
 | WC2844 | T. vegrandis sp. nov. |  | + | + | + | + | + | + |
 | WC2920 | T. vegrandis sp. nov. | + | + | + | - | - | + | + |
 | WC2807 | T. vegrandis sp. nov. | - | - | - | - | - | - | - |
 | WC2841 | T. vegrandis sp. nov. | - | - | - | - | + | - | - |
 | WC2930 | T. vegrandis sp. nov. | - | - | - | - | - | - | - | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | <ROWSPAN=2> Variable | <COLSPAN=4> Campylobacter spp. | <COLSPAN=7> C. jejuni |
 | Coefficient | SE | P value | Coefficient | SE | P value |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Intercept | −1.57 | 0.32 | <0.0001 | −1.71 | 0.44 | NS |

[Assistant]
 | Species |  |  | <0.0011 |  |  | NS1 |
 | Duck | Ref |  |  | Ref |  |  |
 | Starling | 0.42 | 0.13 | <0.001 | −0.13 | 0.18 | NS |
 | Site |  |  | <0.0011 |  |  | <0.0011 |
 | Esplanade | Ref |  |  | Ref |  |  |
 | Hokowhitu | −0.62 | 0.2 | <0.003 | −0.64 | 0.3 | <0.03 |
 | Memorial Park | −0.09 | 0.19 | NS | −0.02 | 0.27 | NS |
 | Massey | −0.6 | 0.2 | <0.004 | −0.67 | 0.3 | <0.02 |
 | Square | −0.21 | 0.2 | NS | −0.1 | 0.28 | NS |
 | Month |  |  | <COLSPAN=5> <0.000011 |  | <0.000011 |
 | August-2008 | 0.73 | 0.31 | <0.05 | 0.59 | 0.52 | NS |
 | September-2008 | 1.58 | 0.3 | <0.001 | 1.72 | 0.48 | <0.001 |
 | October-2008 | 1.56 | 0.3 | <0.001 | 1.68 | 0.48 | <0.001 |
 | November-2008 | 0.57 | 0.31 | NS | 0.54 | 0.52 | NS |
 | December-2008 | Ref |  |  | Ref |  |  |
 | January-2009 | 0.24 | 0.33 | NS | 0.42 | 0.53 | NS |
 | February-2009 | 0.69 | 0.31 | <0.05 | 0.59 | 0.52 | NS |
 | March-2009 | 0.41 | 0.32 | NS | 0.15 | 0.55 | NS |
 | April-2009 | 0.92 | 0.3 | <0.01 | 0.7 | 0.51 | NS |
 | May-2009 | 1.14 | 0.3 | <0.001 | 0.85 | 0.5 | <0.05 |
 | June-2009 | 1.12 | 0.29 | <0.001 | 0.75 | 0.51 | <0.05 |
 | July-2009 | 1.06 | 0.29 | <0.001 | 0.36 | 0.53 | NS | </md>


[User] <|image|>Express the image as Markdown code.

[Assistant]
<md> | Reliability: indicator of the tool's consistency | Validity: determines whether the tool measures what it was designed to measure |
 | --- | --- |
 | Internal consistency: measures the average correlation between all items on a toolIntrarater reliability: an indicator of the tests' stability overtime when it is administered by the same raterInterrater reliability: indicates the consistency of a tool when it is administered by different raters | Construct validity: investigates whether the tool correlates with a theorized constructCriterion validity: can be divided into two categories; concurrent and predictive. Concurrent criterion validity measures the correlation of the tool with other tools that measure the same concepts, preferably a "gold standard" when it exists. Predictive criterion validity examines whether the tool can predict future outcomes.Content validity: assesses whether the tool targets all of the relevant topics related to the concept being measured and that there are no irrelevant itemsFace validity: an assessment of whether the tool appears to measure the intended concept | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | Variable | Target temperature | OR (95 % CI) | P value |
 | --- | ---

[Assistant]
| --- | --- |
 | VF/VT | <34 °C (vs. ≥34 °C) | 19.43 (2.39–158.04) | 0.006 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | Subgroup | Number of studies | Pooled RR(95% CI) | <COLSPAN=2> Q-test for heterogeneity |
 |  |  |  | P value | I2 score |
 | --- | --- | --- |

[Assistant]
--- | --- |
 | <COLSPAN=5> Study design |
 | Cohort studies | 5 | 0.84 (0.42, 1.26) | 0.023 | 64.8% |
 | Case-control studies | 9 | 0.87 (0.54, 1.21) | < 0.001 | 89.7% |
 | Hospital-based case-control studies | 6 | 0.88 (0.40, 1.36) | < 0.001 | 92.5% |
 | Population-based case-control studies | 3 | 0.83 (0.63, 1.03) | 0.586 | 0 |
 | <COLSPAN=5> Geographical region |
 | Europe | 7 | 0.95 (0.49, 1.42) | < 0.001 | 91.9% |
 | US/Canada | 3 | 0.80 (0.58, 1.02) | 0.891 | 0 |
 | Japan | 3 | 0.76 (0.25, 1.27) | 0.019 | 74.7% |
 | <COLSPAN=5> Exposure assessment |
 | Interview | 6 | 0.88 (0.40, 1.36) | < 0.001 | 92.5% |
 | Mailed questionnaire | 7 | 0.84 (0.58, 1.09) | 0.025 | 58.5% |
 | <COLSPAN=5> Case sample size |
 | Large | 7 | 0.99 (0.82, 1.17) | 0.215 | 28.0% |
 | Small | 7 | 0.68 (0.34, 1.02) | < 0.001 | 81.4% | </md>


[User] <|image|>Convert the image into Markdown language.

[Assistant]
<md> | <ROWSPAN=2> Variable | <COLSPAN=2> Univariate Cox regression |
 | HR (95% CI) | P value |
 | --- | --- | --- |
 | Age | <ROWSPAN=2> 1.075 (1.063–1.088) | <ROWSPAN=2> <0.001 |
 | Increasing years |
 | Gender | <ROWSPAN=2> 0.992 (0.737–1.334) | <ROWSPAN=2> 0.957 |
 | Female vs male |
 | WHO grade | <ROWSPAN=2> 9.590 (6.849–13.427) | <ROWSPAN=2> <0.001 |
 | GBM vs low-grade |
 | CDCC109B expression | <ROWSPAN=2> 1.861 (1.699–2.038) | <ROWSPAN=2> <0.001 |
 | High vs low |
 | IDH1 status | <ROWSPAN=2> 0.095 (0.067–0134) | <ROWSPAN=2> <0.001 |
 | Mutation vs wild-type | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | <ROWSPAN=2>  | Mpex | AZ 1 | AZ 2 |
 | (N = 235)* | (N = 749)† | (N = 597)‡ |
 | --- | --- | --- | --- |
 | Age, mean (SD) | 63.7 (8.95) | 62.3 (8.25) | 61.7 (8.27) |
 | Gender, n (% Male) | 113 (48.1) | 572 (76.4) | 443 (74.2) |
 | Race/Ethnicity, n (%) |  |  |  |
 | White | 214 (91.1) | 536 (71.6) | 592 (99.2) |
 | Asian | 2 (0.9) | 212 (28.3) | 0 (0.0) |
 | Black/African American | 18 (7.7) | 0 (0.0) | 0 (0.0) |
 | Hispanic or Latino | 6 (2.6) | 2 (0.3) | 2 (0.3) |
 | FEV1, mean (SD)§ | 1.2 (0.58) | 1.7 (0.49) | 1.6 (0.52) |
 | FEV1% predicted, mean (SD) | 42.2 (18.10) | 58.8 (12.70) | 54.2 (15.36) |
 | GOLD¶ stage, n (%) |  |  |  |
 | 0 | 22 (9.4) | 0 (0.0) | 0 (0.0) |
 | I | 2 (0.9) | 23 (3.2) | 22 (3.8) |
 | II | 55 (23.4) | 503 (69.1) | 300 (51.9) |
 | III | 89

[Assistant]
(37.9) | 197 (27.1) | 240 (41.5) |
 | IV | 66 (28.1) | 5 (0.7) | 16 (2.8) |
 | SGRQ total score∥ | 57.4 (16.21) | 52.6 (18.36) | 54.9 (17.14) |
 | Exercise test meters, mean (SD) | 289 (121)** | 392 (122)** | 337 (185)†† |
 | RS-Total Score, mean (SD)‡‡ | 15.7 (5.93) | 15.9 (6.0) | 18.2 (5.99) |
 | RS-Breathlessness | 8.2 (5.93) | 7.9 (3.17) | 8.9 (3.12) |
 | RS-Cough and Sputum | 4.1 (2.08) | 4.2 (1.56) | 4.7 (1.60) |
 | RS-Chest Symptoms | 3.3 (2.08) | 3.8 (1.93) | 4.6 (1.91) | </md>


[User] <|image|>Transform the figure into Markdown format.

[Assistant]
<md> | Subject | Rest-elbow optimal parameters c and γ | Accuracy (%) |
 | --- | --- | --- |
 | A | 10, 1.7 | 89.3 |
 | B | 90, 0.4 | 89.6 |
 | C | 10, 1.6 | 83.6 |
 | D | 10, 1.5 | 89.4 |
 | E | 10, 2.2 | 87 |
 | F | 15, 1.1 | 86.2 |
 | G | 10, 2 | 89.9 |
 | H | 10, 2.3 | 87 |
 | J | 10, 2 | 95.2 |
 | K | 35, 2.3 | 97.7 |
 | L | 30, 2.1 | 94.9 |
 | M | 10, 1.4 | 90.3 | </md>


[User] <|image|>Express the image as Markdown code.

[Assistant]
<md> | Group Number | Group code | FBS (%) | DMSO (%) | Freezing Medium temp. (oC) |
 | --- | --- | --- | --- | --- |
 | I | 401004 | 40 | 10 | 4 |
 | II | 401025 | 40 | 10 | 25 |
 | III | 401504 | 40 | 15 | 4 |
 | IV | 401525 | 40 | 15 | 25 |
 | V | 402004 | 40 | 20 | 4 |
 | VI | 402025 | 40 | 20 | 25 |
 | VII | 701004 | 70 | 10 | 4 |
 | VIII | 701025 | 70 | 10 | 25 |
 | IX | 701504 | 70 | 15 | 4 |
 | X | 701504 | 70 | 15 | 25 |
 | XI | 702004 | 70 | 20 | 4 |
 | XII | 702025 | 70 | 20 | 25 | </md>


[User] <|image|>Convert the figure into Markdown language.

[Assistant]
<md> | Resource | Unit cost | Reference |
 | --- | --- | --- |
 | <COLSPAN=3> Escitalopram |
 | 28 Tablets, 10 mg | £14.91 | BNF (35) |
 | 28 Tablets, 20 mg | £25.20 |  |
 | GP visit | £25.00 | PSSRU (36) |
 | Psychiatrist consultation (20 min) | £82.00 | PSSRU (36) |
 | Psychologist consultation (60 min) | £66.00 | PSSRU (36) |
 | Nurse visit | £23.50 | PSSRU (36) |
 | Social worker visit (30 min) | £60.00 | PSSRU (36) |
 | <COLSPAN=3> Hospitalisation |
 | Psychiatric ward (per day) | £294.00 | PSSRU (36) |
 | Other ward (per day) | £421.00 | National Reference Costs (37) | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> | Coordinate axes | Combined | Manual coronal | Manual axial | Stereonauta coronal | Stereonauta axial | Atlas based |
 | --- | --- | --- | --- | --- | --- | --- |
 | X |  |  |  |  |  |  |
 | Mean | 0.66 | 2.63 | 2.65 | 2.87 | 2.68 | 3.4 |
 | Range of 95% CI | 0.51-0.81 | 1.35-3.9 | 1.39-3.9 | 1.54-4.2 | 1.4-3.9 | 2-4.8 |
 | SE | 0.07 | 0.64 | 0.63 | 0.66 | 0.62 | 0.7 |
 | Y |  |  |  |  |  |  |
 | Mean | 1.07 | 2.06 | 1.52 | 1.50 | 1.60 | 1.84 |
 | Range of 95% CI | 0.91-1.23 | 1.75-2.37 | 1.2-18 | 1.21-1.78 | 1.29-1.92 | 1.53-2.1 |
 | SE | 0.08 | 0.15 | 0.16 | 0.14 | 0.15 | 0.15 |
 | Z |  |  |  |  |  |  |
 | Mean | 1.01 | 1.55 | 1.48 | 1.26 | 1.53 | 1.76 |
 | Range of 95% CI | 0.85-1.18 | 1.17-1.92 | 1.13-1.82 | 0.98-1.54 | 1.05-2.01 | 1.16-2.37 |
 | SE | 0.08 | 0.18 | 0.17 | 0.13 | 0.24 | 0.30 | </md>


[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Men (n = 100) | <COLSPAN=2> Women (n = 98) |  |
 |  | Mean | SD | Mean | SD | p |
 | --- | --- | --- | --- | --- | --- |
 | ALA, % | 0.15 | 0.14 | 0.19 | 0.14 | 0.06 |
 | EPA, % * | 1.09 | 0.56 | 1.08 | 0.61 | 0.82 |
 | DPA, % | 1.03 | 0.16 | 0.88 | 0.24 | <0.0001 |
 | DHA, % | 3.00 | 0.80 | 3.43 | 0.92 | 0.0005 |
 | total n-3, % | 5.33 | 1.19 | 5.73 | 1.67 | 0.08 | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Each covariate adjusted only for grade | <COLSPAN=2> All covariates and grade, included in the model |
 | Covariates | Odds ratioEstimate (95% CI) | p-value | Odds ratioEstimate (95% CI) | p-value |
 | --- | --- | --- | --- | --- |
 | Restraining factors |  |  |  |  |
 | Academic problems | 0.47 (0.30 to 0.71) | < 0.001 | 0.84 (0.50 to 1.39) | 0.49 |
 | Disturbed work | 0.62 (0.45 to 0.86) | 0.003 | 0.71 (0.46 to 1.11) | 0.13 |
 | Bothered in class | 0.37 (0.23 to 0.61) | < 0.001 | 0.43 (0.22 to 0.85) | 0.02 |
 | Loneliness | 0.47 (0.34 to 0.65) | < 0.001 | 0.74 (0.45 to 1.21) | 0.23 |
 | Victimization | 0.45 (0.32 to 0.62) | < 0.001 | 0.76 (0.48 to 1.22) | 0.26 |
 | Promoting factors |  |  |  |  |
 | School work enjoyment | 1.66 (1.08 to 2.56) | 0.02 | 1.60 (0.93 to 2.77) | 0.09 |
 | Necessary academic help | 2.18 (1.46 to 3.26) | < 0.001 | 0.98 (0.54 to 1.78) | 0.95 |
 | School work satisfaction | 1.42 (0.97 to 2.08) | 0.07 | 1.11 (0.68 to 1.80) | 0.69 |
 | Friends | 1.18 (0.85 to 1.64) | 0.34 | 0.69 (0.44 to 1.07) | 0.10 |
 | Supportive peers | 1.44 (1.08 to 1.93) | 0.01 | 1.31 (0.91 to 1.87) | 0.14 |
 | Supportive teacher | 1.12 (0.83 to 1.50) | 0.45 | 1.00 (0.69 to 1.46) | 0.99 | </md>


[User] <|image|>Convert the image to Markdown syntax.

[Assistant]
<md> |  | Men (n = 6) | Women (n = 5) |
 | --- | --- | --- |
 | Age, y | 41.6 ± 12.2 | 33.7 ± 6.9 |
 | BMR, J/min | 3845 ± 463 | 3808 ± 197 |
 | Height, m | 1.74 ± 0.1 | 1.65 ± 0.1 |
 | Weight, kg | 68.5 ± 6.4 | 62.6 ± 4.1 |
 | BMI, kg/m2 | 22.5 ± 1.5 | 22.9 ± 0.9 |
 | Fat, kg | 15.5 ± 5.0 | 20.2 ± 2.4 |
 | Lean, kg | 50.5 ± 4.5 | 39 ± 2.2 |
 | FFM, kg | 53.0 ± 5.2 | 41.5 ± 2.4 | </md>


[User] <|image|>Express the diagram as Markdown code.

[Assistant]
<md> | Disease/model | QUIN levels | Associated alterations | Reference |
 | --- | --- | --- | --- |
 | Alzheimer | ↑ in demented patient↑ in senile plaques | (i) IDO overexpression(ii) ↓ KYNA(iii) QUIN colocalizes with tau in cortical sections(iv) ↑ QUIN/3-HK quotient in plasma | [25, 26, 91, 92] |
 | Aβ 1-42 | ↑ | (i) IDO over-expression in microglia and macrophages | [93] |
 | Huntington | ↑ | (i) ↑ 3-HK | [94] |
 | Huntingtin transgenic mice | ↑ in YAC128 mice, HdhQ92/HdhQ111 knock-in mice | (i) ↑ 3-HK | [95] |
 | Human immunodeficiency virus (HIV) | ↑ in CSF and serum of patients | (i) Cytokines release (ii) ↑ IDO(iii) QUIN levels enhanced independent blood brain barrier breakdown | [96–98] |
 | Suicide attempters | ↑ in CSF of suicide attempters | (i) An increased QUIN/KYNA quotient | [99] |
 | Depression | ↑ QUIN expression in human brain during acute depressive episodes | (i) Abnormal NMDA receptor function | [100] |
 | Autism | ↑ in CFS of patients | (i) ↑ biopterin(ii) ↓ neopterin | [101] |
 | Amyotrophic lateral sclerosis | ↑ in CSF and serum of patients | (i) ↑ TRP and L-KYN, human leukocyte antigen-DR(ii) IDO over-expression | [102] |
 | Experimental allergic encephalomyelitis, a model of multiple sclerosis | ↑ in the spinal cords of rats | (i) ↑ in KMO activity and 3-HK levels | [103, 104] | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | Parameter | MGUS (n=16) | MM (n=16) |
 | --- | --- | --- |
 | Age, years, median (min-max) | 59 (46-83) | 57 (39-64) |
 | Gender, n, male/female | 8/8 | 5/11 |
 | Paraprotein type, n (%) |  |  |
 | IgG | 11 (69) | 7 (44) |
 | IgA | 4 (25) | 4 (25) |
 | IgD | 1 (6)

[Assistant]
| 0 (0) |
 | Light chain only | 0 (0) | 5 (31) |
 | Bone lesions, n, yes/no | 0/16 | 12/4 |
 | ASCT Induction regime, n (IMiD-based/bortezomib-based)* | NA | 16 (8/8) |
 | Time difference from diagnosis to day 100 after ASCT, days, mean (min-max) | NA | 314 (231-567) |
 | Response on day 100 after ASCT, CR/VGPR/PR, n (%) | NA | 11/4/1 (69/25/6) | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | Genomic feature | Total number of features | G4 overlap | Expected overlap | G4 motif status | FDR adjusted q-value |
 | --- | --- | --- | --- | --- | --- |
 | Promoters | 3,237 | 45 | 27 | Enriched | <0.003 |
 | Dubious ORFs | 71 | 13 | 4 | Enriched | <0.003 |
 | 3′ UTRs | 5,144 | 48 | 34 | Enriched | 0.013 |
 | 5′ UTRs | 5,144 | 47 | 27 | Enriched | 0.003 |
 | Nucleosome-depleted regions | 2,300 | 54 | 18 | Enriched | <0.003 |
 | Meiotic DSB hot spots | 288

[Assistant]
| 112 | 62 | Enriched | <0.003 |
 | Protein-coding ORFs | 5,144 | 303 | 382 | Depleted | <0.003 | </md>


[User] <|image|>Encode the diagram in Markdown syntax.

[Assistant]
<md> | Parameter | CTRL (n = 6) | CM (n = 6) |
 | --- | --- | --- |
 | Body weight (g) | 409 ± 7 | 170 ± 3* |
 | Testis weight (mg) | 1,683 ± 56 | 1,642 ± 193 |
 | Epididymis weight (mg) | 411 ± 12 | 279 ± 38* |
 | Vas deferens weight (mg) | 104 ± 2 | 57 ± 1* |
 | Testis weight / body weight (mg/g) | 4.11 ± 0.14 | 9.66 ± 1.14* |
 | Epididymis weight / body weight (mg/g) | 1.00 ± 0.03 | 1.64 ± 0.22* |
 | Vas deferens weight / body weight (mg/g) | 0.26 ± 0.07 | 0.34 ± 0.08* | </md>


[User] <|image|>Interpret the image as Markdown format.

[Assistant]
<md> | NCBI | Term | Annotation |
 | --- | --- | --- |
 | 15721862 | CR4 | >gi 15721862 dbj BAB68389.1 CR4 [Oryza sativa] |
 | 56201806 | Thioesterase | >gi 56201806 dbj BAD73256.1 putative acyl-(acyl carrier protein) thioesterase [Oryza sativa Japonica Group] |
 | 50843956 | WRKY2 | >gi 50843956 gb AAT84156.1 transcription factor WRKY24 [Oryza sativa Indica Group] |
 | 54111120 | Exonuclease-1 | >gi 54111120 dbj BAD60834.1 exonuclease-1 [Oryza sativa Japonica Group] |
 | 18071363 | Brillarin | >gi 18071363 gb AAL58222.1 AC09088225 putative brillarin [Oryza sativa Japonica Group] |
 | 1586408 | Kinase-like | >gi 1586408 prf 2203451 A receptor kinase-like protein |
 | 50843970 | WRKY10 | >gi 50843970 gb AAT84163.1 transcription factor WRKY100 [Oryza sativa Indica Group] |
 | 58042751 | WRKY30 | >gi 58042751 gb AAW63719.1 WRKY30 [Oryza sativa Japonica Group] |
 | 52076187 | AML1 | >gi 52076187 dbj BAD46727.1 putative AML1 [Oryza sativa Japonica Group] |
 | 30134457 | Arginase | >gi 301344557 gb ADK74000.1 arginase [Oryza sativa Indica Group] | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | Clinical parameters | <COLSPAN=2> WWOX intensity | Total | p value |
 |  | Low (Negative/Weak) | High (Moderate/Strong) |  |  |
 | --- | --- | --- | --- | --- |
 | Grade (GOG) |  |  |  |  |
 | 1 | 4 (23%) | 13 (77%) | 17 | p = 0.707 |
 | 2 | 9 (33%) | 18 (67%) | 27 |  |
 | 3 | 107 (33%) | 215 (67%) | 322 |  |
 | Stage (FIGO) |  |  |  |  |
 | I | 7 (23%) | 24 (77%) | 31 | p = 0.007 |
 | II | 8 (29%) | 20 (71%) | 28 |  |
 | III | 74 (31%) | 168 (69%) | 242 |

[Assistant]
 |
 | IV | 31(48%) | 34 (52%) | 65 |  |
 | Relapse |  |  |  |  |
 | No | 31(32%) | 66 (68%) | 97 | p = 0.09 |
 | Yes | 61(31%) | 137(69%) | 198 |  |
 | Progressive disease | 27(46%) | 32 (54%) | 59 |  |
 | ER |  |  |  |  |
 | Negative | 22 (25%) | 66 (75%) | 88 | p = 0.984 |
 | Positive | 59 (25%) | 176 (75%) | 235 |  |
 | PR |  |  |  |  |
 | Negative | 70 (29%) | 170 (71%) | 240 | p = 0.00 |
 | Positive | 12 (14%) | 71 (86%) | 83 |  | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | Capability | Motivation | Opportunity |
 | --- | --- | --- |
 | An individual’s physical and psychological capacity to engage in the behavior. Includes physical capability (strength, skills, stamina) and psychological capability (knowledge, psychological skills, stamina). | Processes that affect being able to do the behavior at the relevant time and not engage in a competing behavior. Motivation is reflective (self-conscious planning) and evaluation (beliefs about what is good or bad, what will be consequences) and automatic (processes related to wants and needs, desires, reflexes and impulses). | Factors that affect the behavior in the context of the environment both physically and socially. Includes physical opportunity (time, triggers, resources, physical barriers) or social (interpersonal influences, social cues, cultural norms). |
 | Psychological capability Knowledge: Women do not know about family friendly low sugar foods they can prepare or how to incrementally lower total sugars. Skills: Women lack navigational skills for getting physical activity in their postpartum and post-migration lives- given barriers such as unsafe neighborhoods, isolation, lack of familiarity. | Reflective motivation Beliefs: Women do not feel they are ‘supposed’ to focus on exercise for themselves in their roles as mothers (also relates to Social Opportunity, and cultural norms about what mothers can do for ‘themselves’). Outcome expectations: Women do not think their family, especially husband or partner, will go along with reductions in meat consumption, so they do not want to try and have conflict about it. Beliefs: Women believe that they are the cultural custodians of their family’s traditions about food, and have many ideas about how to eat healthier. | Physical opportunity Time: Women feel exhausted and have limited time when they are not caring for others to develop new approaches to preventive behaviors. Resources: Women are often food insecure and feel frustrated at the lack of options for healthy foods. Resources: Women are often eligible for local programs to access fresh produce that align with their desires for naturalness and healthy foods. Access: Women often do not feel they can walk or exercise near their homes which are on crowded streets or in bad neighborhoods. |
 | Physical capability(none identified) | Automatic motivation Reactions to stress: Women often feel stressed about their lives and turn to food to comfort them, often making impulse purchases or eating large portions. | Social opportunity Social norms: Women feel pressured by other women who are experienced mothers to introduce solids and reduce breastfeeding if their babies are fussy. Cues to action: Women do not have the regular reminders they had during pregnancy to help them with diet and exercise. For most of the women, they had nutritionists or other clinic staff, such as health educators, routinely checking in and prompting women to maintain healthy behaviors. Social support: Women often had good experiences with the nutritionist and provider care they received in pregnancy and enjoy discussing healthy eating with others. | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Mean (SD) | Acute mTBI visit 1 | PTS visit 1 | Healthy control visit 1 | Results |
 | --- | --- | --- | --- | --- |
 | N | 11 | 14 | 9 |  |
 | Antisaccade number accepted | 51.9 (25.3) | 55 (21.6) | 72.2 (26.6) | F(2, 31) = 2.01, p = 0.15 |
 | Antisaccade median latency (ms) | 278.36 (28.8) | 272.86 (26.1) | 241.17 (45.2) | F(2, 31) = 3.65, p = 0.04 |
 |  |  |  |  | Post hoc:

[Assistant]
acute > control (confidence limits 7.05, 37.20), PTS > control (−60.34, −3.04) |
 | Antisaccade mean duration (ms) | 85.12 (36.0) | 68.33 (32.5) | 63.45 (17.2) | F(2, 31) = 1.46, p = 0.25 |
 | Antisaccade mean amplitude (°) | 15.48 (5.98) | 13.04 (6.14) | 12.58 (5.36) | F(2, 31) = 0.75, p = 0.48 |
 | Antisaccade mean peak velocity (°/s) | 387.46 (154.38) | 440.92 (259.76) | 437.61 (143.88) | F(2, 31) = 0.25, p = 0.78 |
 | Error median latency (ms) | 178.64 (1.36) | 182.29 (28.9) | 193.17 (39.3) | F(2, 31) = 0.69, p = 0.51 |
 | Error mean duration (ms) | 54.07 (11.3) | 45.96 (3.99) | 45.73 (9.10) | F(2, 31) = 3.63, p = 0.038 |
 |  |  |  |  | Post hoc: acute > PTS (1.29, 14.9), acute > control (0.73, 15.6) |
 | Error mean amplitude (°) | 9.92 (1.47) | 9.36 (2.09) | 8.41 (2.05) | F(2, 31) = 1.58, p = 0.2214 |
 | Error mean peak velocity (°/s) | 432.53 (75.95) | 470.90 (249.19) | 406.85 (101.53) | F(2, 31) = 0.39, p = 0.6808 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | Model | X2 | df | Δχ2 | CFI | TLI | IFI | RMSEA |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Three factor model | 258.68 | 145 |  | .94 | .93 | .94 | .08 |
 | Two factor model: Machiavellian leadership and organizational cynicism | 460.99 | 147 | 202.31** | .83 | .80

[Assistant]
| .83 | .13 |
 | Two factor model: Machiavellian leadership and emotional exhaustion | 472.38 | 147 | 213.70** | .82 | .79 | .82 | .14 |
 | Two factor model: Organizational cynicism and emotional exhaustion | 471.34 | 147 | 212.66** | .82 | .79 | .82 | .14 |
 | One factor model | 658.36 | 148 | 399.68** | .72 | .68 | .72 | .17 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> |  | Sum of squares | Mean square | Num DF | Den DF | F | Pr > F |
 | --- | --- | --- | --- | --- | --- | --- |
 | Cognate condition | 0.03 | 0.03 | 1 | 1120.88 | 0.29 | 0.587 |
 | Target language | 1.17 | 1.17 | 1 | 1144.22 | 11.76 | 0.001 |
 | Language dominance | 0.21 | 0.11 | 2 | 43.14 | 1.08 | 0.350 |
 | Number of syllables | 0.94 | 0.94 | 1 | 1118.41 | 9.46 | 0.002 |
 | Response time preceding trial | 0.67 | 0.67 | 1 | 1158.73 | 6.72 | 0.010 |
 | Cognate condition * target language | 0.43 | 0.43 | 1 | 1156.19 | 4.32 | 0.038 |
 | Cognate condition * language dominance | 0.91 | 0.46 | 2 | 1120.62 | 4.60 | 0.010 |
 | Target language * language dominance |

[Assistant]
0.31 | 0.15 | 2 | 1139.40 | 1.54 | 0.215 |
 | Cognate condition * target language * language dominance | 0.02 | 0.01 | 2 | 1156.67 | 0.10 | 0.903 | </md>


[User] <|image|>Convert the illustration into Markdown format.

[Assistant]
<md> |  | <COLSPAN=7> Year of entry to the course |
 |  | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | Total |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Standard pathway entrants | 106 | 93 | 101 | 124 | 122 | 121 | 667 |
 | Ineligible for inclusion |  |  |  |  |  |  |  |
 | Did not complete MSOD questionnaire | 24 | 4 | 9 | 12 | 12 | 17 | 78 |
 | Did not respond to question on intended practice location | 7 | 15 | 10 | 7 | 3 | 9 | 51 |
 | Included in the study | 75 | 74 | 82 | 105 | 107 | 95 | 538 | </md>


[User] <|image|>Transcribe the photo into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> QALYb = 10 000 USD | <COLSPAN=2> QALY = 50 000 USD | <COLSPAN=2> QALY = 100 000 USD |
 |  | EQ-5D-3 L | SF-6D | EQ-5D-3 L | SF-6D | EQ-5D-3 L | SF-6D |
 | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Follow-up | 46.3 | 5.4 | 1441.6 | 1237.0 | 3185.7 | 2776.6 |
 | (-477.4–582.1) | (-324.5–344.0) | (-1137.4–4067.4) | (-398.4–2867.9) | (-1961.7–8426.6) | (-492.2–6030.0) |
 | <ROWSPAN=2> Follow-up + 1 year | 559.9 | 432.9 | 4009.7 | 3374.4 | 8321.8 | 7051.3 |
 | (-483.9–1627.1)c | (-268.5–1135.6) | (-1180.8–9268.4) | (-106.0–6827.5) | (-2085.7–18833.4) | (100.2–13953.2) |
 | Follow-up + 3 years | 1542.6 | 1251.2 | 8923.2 | 7466.1 | 18148.9 | 15234.8 |
 |  | (-609.2–3698.0) | (-173.2–2664.1) | (-1774.5–19682.4) | (367.5-14559.2) | (-3235.4–39619.4) | (1030.6–29422.1) | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> | <COLSPAN=4> Father | <ROWSPAN=2>  | <COLSPAN=4> Mother |
 | Not at all true (0) | Somewhat true (1) | True (2) | Very true (3) | Not at all true (0) | Somewhat true (1) | True (2) | Very true (3) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 |  |  |  |  | 1. This parent warns me about potential dangers, to prevent accidents from happening |  |  |  |  |
 |  |  |  |  | 2. When I am anxious to do something, this parent cannot conceal his/her worries |  |  |  |  |
 |  |  |  |  | 3. This parent explicitly warns me that I should be careful when I leave home |  |  |  |  |
 |  |  |  |  | 4. This parent warns me that I should never talk to strangers because of bad things that might happen |  |  |  |  |
 |  |  |  |  | 5. When this parent is scared, his/her body language reveals his/her fear (e.g., fidgeting hands, sweating, trembling, touching neck or face) |  |  |  |  |
 |  |  |  |  | 6. This parent shows when he/she is in panic in my presence |  |  |  |  |
 |  |  |  |  | 7. When this parent is scared, he/she has a fearful expression on his/her face in my presence |  |  |  |  |
 |  |  |  |  | 8. This parent shows me that he/she is afraid to do certain things |  |  |  |  |
 |  |  |  |  | 9. This parent warns me explicitly that I should avoid dangerous situations |  |  |  |  |
 |  |  |  |  | 10. This parent tells me that the world is not always a safe place |  |  |  |  |
 |  |  |  |  | 11. Even if this parent tries to hide his/her fear, I can still see that he/she is anxious |  |  |  |  |
 |  |  |  |  | 12. When I do something new or go to a new place, this parent warns me about the things that could go wrong |  |  |  |  |
 |  |  |  |  | 13. This parent points out to me that an accident can always happen |  |  |  |  |
 |  |  |  |  | 14. This parent warns me explicitly not to go along with unfamiliar people |  |  |  |  | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | astA gene sequence type | <COLSPAN=2> N (%) of strains from: | Serogroup ( n ) |
 |  | Diarrheic children | Non-diarrheic children |  |
 | --- | --- | --- | --- |
 | 042-type EAST1 | 24 (14.3) | 1 (1.8)a | O9 (1), O33 (2), O108 (2), O111 (1), O119 (8), O142 (1), O152 (1), O157 (1), O169 (1), OND (7) |
 | EAST1v5 | 6 (3.6) | 1 (1.8) | O26 (1), O9 (1), O96 (1) O111 (1), O141 (1), ONT (2) |
 | type 1 SHEAST | 6 (3.6) | 1 (1.8) | O26 (1), O55 (1), O103 (1), O153 (1), OND (3) |
 | type 2 SHEAST | 2 (1.2) | 0 | O26 (1), O55 (1) |
 | mutant

[Assistant]
| 7 | 6 | O26 (3), O55 (1), O111 (5), O119 (1), O127 (2), ONT (1) |
 | Total | 45 | 9 |  | </md>


[User] <|image|>Convert the illustration into Markdown format.

[Assistant]
<md> |  |  |  |  |  | <COLSPAN=2> Monitor ion (m/z) |
 | Chemical name | CAS No. | Purity (%) | Supplier1 | Retention time (min) | Quantifying ion | Qualifying ion |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=7> Standard |
 | 1,3-Butadiene2 | 106-99-0 | >95 | A | 6.1 | 54 | 39, 53 |
 | Acrylonitrile2 | 107-13-1 | >99.8 | B | 10.7 | 53 | 52 |
 | Benzene | 71-43-2 | >99 | C | 13.2 | 78 | 52 |
 | Methyl isobutyrate | 547-63-7 | >95 | D | 13.6 | 43 | 71, 41 |
 | Methyl methacrylate | 80-62-6 | >99.8 | E | 14.1 | 69 | 41 |
 | 1-Octene | 111-66-0 | >95 | D | 14.9 | 55 | 70 |
 | Toluene | 108-88-3 | >99.5 | F | 15.0 | 91 | 92 |
 | 4-Vinyl-l-cyclohexene | 100-40-3 | >95 | D | 15.8 | 79 | 54, 91 |
 | Ethylbenzene | 100-41-4 | >99 | D | 16.3 | 91 | 106 |
 | p-Xylene | 106-42-3 | >98 | D | 16.4 | 91 | 106 |
 | Styrene | 100-42-5 | >99 | D | 16.8 | 104 | 78 |
 | Isopropylbenzene | 98-82-8 | >98 | D | 17.0 | 105 | 120, 91 |
 | Propylbenzene | 103-65-1 | >97 | D | 17.4 | 91 | 102, 105 |
 | α-Methylstyrene | 98-83-9 | >98 | D | 17.7 | 118 | 117, 91 |
 | <COLSPAN=7> Internal standard |
 | 1,2-Butadiene2 | 590-19-2 | >95 | A | 7.2 | 54 | 53, 39 |
 | Isobutyronitrile | 78-67-1 | >99 | E | 13.1 | 68 | 42 |
 | p-Diethylbenzene | 105-05-5 | >99 | D | 18.3 | 105 | 117, 120 | </md>


[User] <|image|>Translate the diagram into Markdown format.

[Assistant]
<md> | <COLSPAN=2>  | JAK2V617F-mutated ET | CALR-mutated ET |
 | --- | --- | --- | --- |
 | Age, sex |  | Older | Younger, M>F |
 | <ROWSPAN=3> Blood counts | Hemoglobin | Higher | Lower |
 | Platelet | Lower | Higher |
 | White blood count | Higher | Lower |
 | <COLSPAN=2> Serum erythropoietin level | Lower | Higher |
 | <COLSPAN=2> Thrombotic risk | Higher | Lower |
 | <COLSPAN=2> Polycythemic risk | Cumulative risk 29% at 15 years | No transformation to PV |
 | <COLSPAN=2> MF transformation risk |  | Conflicting results |
 | <COLSPAN=2> Overall survival (OS) | Long-term OS similar to that in CALR-mutated ET | Long-term OS similar to that in JAK2V617F-mutated ET |
 | <COLSPAN=2> Treatment implications |  | ET patients with CALR mutations are at a lower risk of thrombotic complications compared to those with JAK2 mutations; however, recommendations regarding modifications of current treatment based on mutation status have not been developed yet | </md>


[User]
<|image|>What are the following image content in markdown style: <md> |  | Pre-screening | Screening | Baseline | <COLSPAN=3> Follow-up |
 | Visit |  |  | 1 | 2 | 3 | 4 (phone call only) |
 | Assessmentsa | Within 3 months of baseline visit | Week −4 to −1 | Day 0 | Week 12 (+/− 7 days) | Week 24 (+/− 7 days) | Week 25 (+/− 3 days) |
 | --- | --- | --- | --- | --- | --- | --- |
 | Identification and initial approach (including provision of PIS) | X |  |  |  |  |  |
 | Eligibility criteria checked (as per routine clinical practice) | X |  |  |  |  |  |
 | Written informed consent (including discussion of study in detail, questions answered) |  | X |  |  |  |  |
 | Physical examination (height,e weight, blood pressure, pulse) |  |  | X |  | X |  |
 | Venepuncture |  |  | Xb | Xc |

[Assistant]
Xd |  |
 | Clinical history (relevant medical history, medication list/history) |  |  | X |  |  |  |
 | Participant-completed questionnaires (ThyDQoL, ThySRQ, EQ-5D) |  |  | X |  | X |  |
 | Nurse-administered questionnaires (FRAT, TUG) |  |  | X |  | X |  |
 | Randomization (after all eligibility criteria checked and written informed consent obtained) |  |  | X |  |  |  |
 | Study medication prescribed and dispensed (following LT4 dose assessment at visit 2 only) |  |  | X | X |  |  |
 | Study medication compliance checks |  |  |  | X | X |  |
 | Concomitant medication |  |  | X | X | X |  |
 | Adverse events |  |  |  | X | X |  |
 | Serious adverse events |  |  |  | X | X | X | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> | Problem size (n+) | Quartic algorithm:compute all D-values | Thresholded algorithm |
 | --- | --- | --- |
 | 8 | 0.05 s | 0.07 s |
 | 16 | 0.19 s | 0.15 s |
 | 32 | 0.92 s | 0.36 s |
 | 64 | 6.16 s | 0.61 s |
 | 128 | 53.15 s | 2.35 s |
 | 256 | 689.18 s | 5.93 s |
 | 512 | 7864.20 s | 19.54 s |
 | 1024 | > 1 d | 85.76 s | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | Datasets | G(A) | G(A + X) | Gc(A + X) | G(A) + G(X) | G(A) + Pol | Gc(A + X) + Pol |
 | --- | --- | --- | --- | --- | --- | --- |
 | 54K_real | 0.881 | 0.885 | 0.885 | 0.885 | 0.918 | 0.919 |
 | IMP_test | 0.881 | 0.885 | 0.885 | 0.885 | 0.918 | 0.919 |
 | IMP_0.5ref | 0.881 | 0.886 | 0.885 | 0.886 | 0.920 | 0.922 |
 | LD_real | 0.834 | 0.835 | 0.837 | 0.838 | 0.914 | 0.915 | </md>


[User] <|image|>Convert the figure into Markdown format.

[Assistant]
<md> | No. | Cultivar name | Type | No. | Cultivar name | Type |
 | --- | --- | --- | --- | --- | --- |
 | 1 | 'Koushuu Koume' | P. mume | 21 | 'Shantao' | P. persica |
 | 2 | 'Zaohuamei' | P. mume | 22 | 'Xuanchengtiantao' | P. persica |
 | 3 | 'Lv' e mei' | P. mume | 23 | 'Maotao' | P. persica |
 | 4 | 'Qijiangxingmei' | P. mume e | 24 | 'Qidongyoutao' | P. persica |
 | 5 | 'Shuangtaomei' | P. mume | 25 | 'Huozhu' | P. persica |
 | 6 | 'Sichaunbaimei' | P. mume | 26 | 'Taobadan' | P. persica |
 | 7 | 'Zhizhimei' | P. mume | 27 | 'Xiaguang' | P. persica |
 | 8 | 'Dayezhugan' | P. mume | 28 | 'Baifeng' | P. persica |
 | 9 | 'Gyokuei' | P. mume | 29 | 'Xinjianghuangrou' | P. persica |
 | 10 | 'Wanhong' | P. mume | 30 | 'Pingbeizi' | P. persica |
 | 11 | 'Hongmei' | P. mume | 31 | 'Dalimei' | P. salicina |
 | 12 | 'Oushuku' | P. mume | 32 | 'Dongbeili' | P. salicina |
 | 13 | 'Henghe' | P. mume | 33 | 'Xiaosuli' | P. salicina |
 | 14 | 'Xianmimei' | P. mume | 34 | 'Bulin' | P. salicina |
 | 15 | 'Xiao'ou gongfen' | P. mume | 35 | 'Chuandaojiutian' | P. salicina |
 | 16 | 'Shinano Koume' | P. mume | 36 | 'Dashizaosheng' | P. salicina |
 | 17 | 'Taoxingmei' | P. mume | 37 | 'Aoli' | P. salicina |
 | 18 | 'Momei' | P. mume | 38 | 'Xiangjiaoli' | P. salicina |
 | 19 | 'Koushuu Saisyou' | P. mume | 39 | 'Gaixiandali' | P. salicina |
 | 20 | 'Gojirou' | P. mume | 40 | 'Changli15' | P. salicina | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Subject ID | <ROWSPAN=2> Exposure date | <ROWSPAN=2> Sampling date | <ROWSPAN=2> Status at exposure | <ROWSPAN=2> Exposed MERS case ID1 | <ROWSPAN=2> Underlying disease | <ROWSPAN=2> Symptoms after exposure | <COLSPAN=2> ELISA | <ROWSPAN=2> IFA | <ROWSPAN=2> PRNT |
 | Ratio | Result |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1 | May 15 | Nov 1 | Patient | #1 | Angina | None | 0.996 | Borderline | Positive | Positive |
 | 2 | May 16 | Nov 2 | Patient | #1 | None | None | 2.078 | Positive | Negative | Negative |
 | 3 | May 15 | Nov 2 | Healthcare worker | #1 | None | Fatigue | 1.640 | Positive | Negative | Negative |
 | 4 | Jun 9 | Oct 31 | Patient | #118 | Hypertension | Blurred vision | 1.116 | Positive | Negative | Negative |
 | 5 | Jun 4 | Nov 8 | Patient | #89 | Hypertensive heart disease | None | 0.916 | Borderline | Negative | Negative |
 | 6 | Jun 5 | Nov 9 | Patient | #89 | Lumbar spinal Fatigue stenosis |  | 1.724 | Positive | Negative | Negative |
 | 7 | Jun 11 | Nov 8 | Patient | #89 | None | Fatigue and | 0.985 | Borderline | Negative | Negative | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> | City | Parks | Park Area (ha) | Parks per 10,000 Residents | Park Area per Capita (m2) | Parkland as a Percentage of Urban Area |
 | --- | --- | --- | --- | --- | --- |
 | Beijing | 282 | 28,798 | 0.15 | 15.49 | 2.36% |
 | Tianjin | 94 | 2124 | 0.12 | 2.70 | 0.89% |
 | Shanghai | 161 | 2301 | 0.06 | 0.95 | 0.36% |
 | Wuhan | 74 | 3110 | 0.12 | 4.90 | 2.14% |
 | Guangzhou | 245 | 5180 | 0.22 | 4.69 | 3.71% |
 | Shenzhen | 889 | 21,953 | 0.82 | 20.37 | 10.99% |
 | Chongqing | 307 | 10,751 | 0.25 | 8.65 | 1.62% | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> | Communication skills – written, verbal, patient advocacy and conflict resolution, dealing with difficult clients |
 | --- |
 | Legal and ethical issues-including confidentiality and national privacy principles |
 | Infection control – wound care and management |
 | first aid and CPR |
 | Chronic disease management – physical assessment, palliative and end of life care |
 | Cold chain monitoring |
 | Sterilization |
 | Triage |
 | Prevention and health education – counselling, health education and promotion, family planning, child health, screening, immunization, mental health, drug (including tobacco) and alcohol screening and brief interventions |
 | Management skills – case management, practice accreditation, information technology, recall/reminder register. | </md>


[User] <|image|>Render the diagram in Markdown format.

[Assistant]
<md> |  | <COLSPAN=3> Difference of index scores |
 |  | Mean (SD) | Min | Max |
 | --- | --- | --- | --- |
 | Same group | 0.18 (0.33) | 0 | 0.97 |
 | Subsequent group | 0.37 (0.4) | 0 | 1 | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> | Site of pain | Total | Male | Female | Young (20–44) | Middle-aged (45–59) | Elderly (60–89) |
 | --- | --- | --- | --- | --- | --- | --- |
 | Neck | 227 (37.8%) | 107 (35.7%) | 120 (40.0%) | 97 (48.5%) | 69 (34.5%) | 61 (30.5%) |
 | Shoulder | 348 (58.0%) | 160 (53.3%) | 188 (62.7%) | 118 (59.0%) | 125 (62.5%) | 105 (52.5%) |
 | Arm | 127 (21.2%) | 57 (19.0%) | 70 (23.3%) | 47 (23.5%) | 45 (22.5%) | 35 (17.5%) |
 | Hand/wrist | 153 (25.5%) | 67 (23.3%) | 86 (28.7%) | 57 (28.5%) | 50 (25.5%) | 46 (23.0%) |
 | Upper back | 158 (26.3%) | 76 (25.3%) | 82 (27.3%) | 66 (33.0%) | 54 (27.0%) | 38 (19.0%) |
 | Lower back | 410 (68.3%) | 207 (69.0%) | 203 (67.7%) | 146 (73.0%) | 124 (62.0%) | 140 (70.0%) |
 | Hip (joint) | 98 (16.3%) | 40 (13.3%) | 58 (19.3%) | 36 (18.0%) | 32 (16.0%) | 30 (15.0%) |
 | Knee | 229 (38.2%) | 100 (33.3%) | 129 (43.0%) | 61 (30.5%) | 70 (35.0%) | 98 (49.0%) |
 | Foot/ankle | 132 (22.0%) | 62 (20.7%) | 70 (23.3%) | 52 (26.0%) | 40 (20.0%) | 40 (20.0%) |
 | Other | 3 (0.5%) | 2 (0.7%) | 1 (0.3%) | 0 (0.0%) | 1 (0.5%) | 2 (1.0%) |
 | Total | 600 | 300 | 300 | 200 | 200 | 200 | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> | Study drug | Dosage and administration (oral) | <COLSPAN=2> Usual daily dose |
 |  |  | Increased AII antagonist dose group | Combined amlodipine group |
 | --- | --- | --- | --- |
 | Blopress® tablets | o.d. | 12 mg | 8 mg |
 | Nu-lotan® tablets | o.d. | 100 mg | 50 mg |
 | Micardis® capsules | o.d. | 80 mg | 40 mg |

[Assistant]
| Diovan® tablets | o.d. | 160 mg | 80 mg |
 | Olmetec® tablets | o.d. | 40 mg | 20 mg |
 | Amlodin® tablets, or Norvasc® tablets | o.d. | n/a | 5 mg | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Tertiary MDT (N = 47) | <COLSPAN=2> Secondary MDT(N = 30) |
 | --- | --- | --- | --- | --- |
 | Professional Group | Number | % | Number | % |
 | Cardiologist | 36 | 76 | 15 | 50 |
 | Obstetrician(Advanced or sub-specialist trained in maternal medicine) | 31 | 66 | 11 | 37 |
 | Anaesthetist | 30 | 64 | 14 | 47 |
 | <COLSPAN=5> Midwife: |
 | Specialist cardiac midwife | 11 | 23 | 3 | 10 |
 | Woman’s named midwife | 3 | 6 | 1 | 3 |
 | Other midwife | 17 | 36 | 6 | 20 |
 | Fetal cardiologist | 14 | 30 | 3 | 10 |
 | Obstetric Physician | 9 | 19 | 5 | 17 |
 | Obstetrician | 9 | 19 | 8 | 27 |
 | Specialist nurse | 4 | 9 | 1 | 3 |
 | Neonatologist | 4 | 9 | 3 | 10 |
 | GP | 1 | 2 | 0 | 0 |
 | Intensivist | 1 | 2 | 0 | 0 |
 | Other physician | 1 | 2 | 4 | 13 |
 | OtherGUCH consultant; Cardiology technicians; fetal medicine midwives, haematologists | 4 | 9 | 0 | 0 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> |  |  |  |  | <COLSPAN=6> Percentiles |
 |  | n | GM | Mean | 10th | 25th | 50th | 75th | 90th | 95th |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1st Visit | 56 | 2.66 | 5.10 | 1.28 | 1.40 | 1.84 | 3.77 | 10.85 | 26.14 |
 | 2nd Visit | 56 | 4.46 | 6.55 | 2.50 | 3.23 | 4.40 | 7.25 |

[Assistant]
12.10 | 19.13 |
 | 3rd Visit | 56 | 3.10 | 5.00 | 1.25 | 2.66 | 3.78 | 5.23 | 9.15 | 14.25 |
 | NHANES 2003-06 | 8556 | 0.82 | NAa | 0.23 | 0.40 | 0.80 | 1.60 | 3.02 | 4.47 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Outcome Belief | Odds Ratio | 95% Confidence Limits |
 | --- | --- |

[Assistant]
--- |
 | Make employees healthier | 2.02 | 1.51, 2.70 |
 | Lower costs | 1.50 | 1.06, 2.11 |
 | Show that I care | 1.39 | 1.08, 1.80 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Respondents | n | Column % |
 | --- | --- | --- |
 | Overall | 14 |  |
 |

[Assistant]
<COLSPAN=3> Sex |
 | Male | 6 | 43 |
 | Female | 8 | 57 |
 | <COLSPAN=3> Nationality |
 | USA | 7 | 50 |
 | Botswana | 5 | 36 |
 | Other | 2 | 14 |
 | <COLSPAN=3> Role in research |
 | Principal investigators | 6 | 43 |
 | Other healthcare professional | 1 | 7 |
 | Research coordinators | 2 | 14 |
 | Laboratory technicians | 2 | 14 |
 | Research assistants | 3 | 22 |
 | <COLSPAN=3> Trials conducted (n) |
 | 1–3 | 10 | 72 |
 | 4–7 | 2 | 14 |
 | 8+ | 2 | 14 | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> | <ROWSPAN=2> Day | <COLSPAN=2> Pooled Kaplan–Meier estimates |
 | Naïve approacha | D + L approach meta-analysisb |
 | --- | --- | --- |
 | 7 | 1.000 | 0.994 [0.987–1.000] |
 | 14 | 0.994 [0.989–1.000] |

[Assistant]
0.989 [0.979–0.998] |
 | 21 | 0.949 [0.933–0.966] | 0.943 [0.916–0.970] |
 | 28 | 0.918 [0.895–0.941] | 0.909 [0.873–0.948] | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> |  | <COLSPAN=3> Adjusted regression coefficients (95% Confidence Intervals) |
 | Variables | All children | Boys | Girls |
 | --- | --- | --- | --- |
 | Sex |  |  |  |
 | Boys | 0 |  |  |
 | Girls | 0.07 (0.02, 0.11) |  |  |
 | Child's ethnicity |  |  |  |
 | White | 0 | 0

[Assistant]
| 0 |
 | Indian | −0.39 (−0.59, −0.19) | −0.45 (−0.81, −0.09) | −0.33 (−0.57, −0.10) |
 | Pakistani | −0.38 (−0.53, −0.24) | −0.52 (−0.72, −0.33) | −0.25 (−0.41, −0.09) |
 | Bangladeshi | −0.20 (−0.42, 0.02) | −0.29 (−0.54, −0.04) | −0.10 (−0.42, 0.22) |
 | Black | 0.24 (0.06, 0.41) | 0.16 (−0.05, 0.37) | 0.33 (0.15, 0.51) |
 | Mixed/Other | −0.20 (−0.33, −0.06) | −0.24 (−0.44, −0.03) | −0.16 (−0.34, 0.02) | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> | <COLSPAN=2> pSBTN-AB31 constructa | <COLSPAN=2> pSBTN-AB30 constructa | <COLSPAN=3> Theoretical peptides |
 | --- | --- | --- | --- | --- | --- | --- |
 | [MH]+ observed (in amu) | Δmass (in ppm) | [MH]+ observed (in amu) | Δmass (in ppm) | [MH]+ expected (in amu) | Positionb (Start-End) | Peptide assignment |
 | 1590.64 | -31 | nd c | - | 1590.69 | 3–16 | GSHHHHHHGMASMK |
 | nd c | - | 1050.54 | -19 | 1050.56 | 17–24 | VYIIDYHK |
 | 1505.71 | -33 | nd c | - | 1505.76 | 17–28 | VYIIDYHKDDPK |
 | 1661.83 | -18 | 1661.85 | -6 | 1661.86 | 17–29 | VYIIDYHKDDPKR |
 | 1601.84 | -31 | 1601.83 | -37 | 1601.89 | 49–63 | GVVLDPFAQITLSNK |
 | 1844.98 | -16 | 1845.00 | -5 | 1845.01 | 49–65 | GVVLDPFAQITLSNKD |
 | 2328.28 | -4 | 2328.28 | -4 | 2328.29 | 49–69 | GVVLDPFA...KDKDIVR |
 | 2484.35 | -16 | 2484.34 | -20 | 2484.39 | 49–70 | GVVLDPFA...KDKDIVRR |
 | 2140.06 | 0 | 2140.06 | 0 | 2140.06 | 71–89 | IGITIVDTSWNNTSQSEFK |
 | 2296.16 | 0 | 2296.16 | 0 | 2296.16 | 70–89 | RIGITIVDTSWNNTSQSEFK |
 | 2043.17 | 10 | 2043.18 | 15 | 2043.15 | 97–114 | RIPILFAGNPIHYGIAYK |
 | 1887.05 | 0 | 1887.06 | 5 | 1887.05 | 98–114 | IPILFAGNPIHYGIAYK

[Assistant]
|
 | 1244.62 | -16 | 1244.59 | -40 | 1244.64 | 143–152 | WGHTFIELNK |
 | 2091.09 | 0 | nd c | - | 2091.09 | 143–159 | WGHTFIELNKELLEAYK |
 | nd c | - | 865.53 | 69 | 865.47 | 153–159 | ELLEAYK | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Protein | Ligand | Protomol | Total Score | C Score |
 | --- | --- | --- | --- | --- |
 | 2R2N | pdb2r2n_ligand | Ligand extraction | 8.053 | 5 |
 | 2R2N | Kynurenine_z | Ligand extraction | 6.1745 | 4 |
 | 2R2N | FC101b_inactive | Ligand extraction | 7.3148 | 2 |
 | 2R2N | FC101a_04 | Ligand extraction | 6.5068 | 1 |
 | 2QLR | pdb2r2n_ligand | Automatic mode |

[Assistant]
5.1002 | 5 |
 | 2QLR | Kynurenine_z | Automatic mode | 4.3048 | 5 |
 | 2QLR | FC101b_inactive | Automatic mode | 6.2713 | 4 |
 | 2QLR | FC101a_04 | Automatic mode | 5.2248 | 2 | </md>


[User] <|image|>What are the following table content in markdown style: <md> | BCR-ABL t(9;22) (sample) | NTC | Result

[Assistant]
|
 | --- | --- | --- |
 | No amplification | Negative | Negative |
 | Amplification signal | Negative | Positive for BCR-ABL t(9;22) fusion transcripts |
 | Amplification signal | Positive | Contamination, repeat experiment | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | Rice Chromosome | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Total |
 | --- | --- | --- | --- | --- | --- | --- |

[Assistant]
--- | --- | --- | --- | --- | --- | --- |
 | Number of loci | 122 | 95 | 133 | 52 | 64 | 61 | 52 | 43 | 41 | 23 | 27 | 30 | 743 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | Mean Total Time (sec) | <COLSPAN=3> RNA2(∼1300 bases) | <COLSPAN=3> RNA1(∼3100 bases) |
 | --- | --- | --- | --- | --- | --- | --- |
 |  | 60 | 150 | 300 | 60 | 150 | 300 |
 | Centered | 257.7 | 232.3 | 185.7 | 3228.7 | 2871.7 | 2303.9 |
 | Optimized | 226.6 | 197.4 | 164.6 | 2758.0 | 2366.0 | 1907.7 |

[Assistant] | Opti./Cent. | 0.88 | 0.85 | 0.89 | 0.85 | 0.82 | 0.83 | </md>


[User] <|image|>Express the picture as Markdown code.

[Assistant]
<md> | Kit name | Manufacturer | Venipuncture | Test readout | Chemical basis | Cold storage | Laboratory equipment/skills | Cost/test |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | G6PD deficiency | Trinity Biotech, Ireland | Yes | Quantitative | Spectrophotometric | Yes | Yes |  |
 | G-Six Kinetic | Tulip Group, India | Yes | Quantitative | Spectrophotometric | Yes | Yes | $1.10 |
 | R&D G6PD quantitative | N. Dimopoulos S.A., Greece | Optional | Quantitative | Spectrophotometric | Yes | Yes | $0.26–2.50* |
 | R&D G6PD qualitative | N. Dimopoulos S.A., Greece | Optional | Qualitative | Ultra-violet fluorescence | Yes | Yes | $0.18 |
 | G6PD-WST | Dojindo, Japan | Optional | Qualitative | Dye reduction | Yes | Yes | $2.00 |
 | G-SIX | Tulip Group, India | Yes | Qualitative | Met-Hb reduction | No | Yes | $1.12 |
 | G6PD deficiency | Trinity Biotech, Ireland | Yes | Qualitative | Ultra-violet fluorescence | Yes | Yes |  |
 | G6PD deficiency | Trinity Biotech, Ireland | Yes | Qualitative | Dye reduction | Yes | Yes |  |
 | MBK | Span, India | Yes | Qualitative | Dye reduction | Yes | Yes |  |
 | BinaxNOW G6PD | Alere/Inverness Medical, United States | Yes | Qualitative | Dye reduction | No | No | $16.00 |
 | CareStart G6PD | AccessBio, United States | No | Qualitative | Dye reduction | No | No | $1.50 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | All Groups (n = 35) | r | p |
 | --- | --- | --- |
 | Mechanical properties |  |  |
 | Fmax | 0.667 | ˂0.01 |
 | Pmax | 0.603 |

[Assistant]
˂0.01 |
 | Microstructural properties |  |  |
 | Cr.Wi | 0.460 | ˂0.05 |
 | Tb.Th | 0.466 | ˂0.01 |
 | Tb.Sp | −0.558 | ˂0.01 |
 | Femur mineral content |  |  |
 | Calcium | 0.544 | ˂0.05 |
 | Phosphorus | N.S. | N.S. |
 | Potassium | 0.654 | ˂0.05 |
 | Magnesium | N.S. | N.S. |
 | Ca/P ratio | 0.583 | ˂0.01 | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | n | Age | Female (%) | Duration of tinnitus in months | Laterality | THI at baseline |
 | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=3> Study 1 (n = 15) | <ROWSPAN=3> 60.6 ± 9.6 | <ROWSPAN=3> 40 | <ROWSPAN=3> 107.8 ± 118.7 | 5 unilateral | <ROWSPAN=3> 56.8 ± 28.2 |
 | 7 bilateral |
 | 3 in head |
 | <ROWSPAN=2> Study 2 (n = 16) | <ROWSPAN=2> 62.8 ± 10.6 | <ROWSPAN=2> 31.3 | <ROWSPAN=2> 78.8 ± 147.9 | 11 unilateral | <ROWSPAN=2> 52.8 ± 30.5 |
 | 5 bilateral | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | <ROWSPAN=2> Measure | <COLSPAN=2> Night 1 | <COLSPAN=2> Night 2 | <COLSPAN=2> Night 3 |
 | NM | HC | NM | HC | NM | HC |
 | --- | --- | --- | --- | --- | --- | --- |
 | Sleep quality | 2.63 ± 0.64 | 3.03 ± 0.81 | 3.44 ± 0.58 | 3.49 ± 0.69 |

[Assistant]
3.33 ± 0.60 | 3.75 ± 0.51 |
 | Feeling of being refreshed after sleep | 2.49 ± 0.59 | 3.13 ± 0.83 | 2.85 ± 0.72 | 3.20 ± 0.84 | 2.82 ± 0.61 | 3.40 ± 0.78 |
 | Feeling balanced/relaxed in the evening | 3.19 ± 0.70 | 3.63 ± 0.65 | 3.36 ± 0.78 | 3.73 ± 0.57 | 3.29 ± 0.58 | 3.93 ± 0.60 |
 | Feeling exhausted in the evening | 2.98 ± 0.72 | 2.81 ± 0.78 | 2.94 ± 0.56 | 2.94 ± 68 | 3.06 ± 0.54 | 2.91 ± 0.74 |
 | Psychosomatic symptoms while sleeping | 1.79 ± 0.52 | 1.76 ± 0.49 | 1.67 ± 0.65 | 1.68 ± 0.47 | 1.49 ± 0.47 | 1.60 ± 0.43 | </md>


[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> |  | MiRNA |
 | --- | --- |
 | Positive set | let-7, lin-4, lsy-6, miR-273, miR-61, miR-84 |
 |  | bantam, let-7, miR-1, miR-11, miR-2, miR-278, miR-2a-1, miR-4, miR-7, miR-79 |
 |  | let-7 |
 |  | miR-125b, miR-134, miR-181a |
 |  | let-7, let-7b, let-7e, miR-1, miR-101, miR-103-1, miR-10a, miR-125a, miR-125b, miR-127, miR-130, miR-132, miR-133, miR-136, miR-141, miR-143, miR-145, miR-15, miR-16, miR-17-5p, miR-196, miR-199b, miR-19a, miR-1b, miR-20, miR-221, miR-222, miR-223, miR-23, miR-23a, miR-24, miR-26, miR-32, miR-34, miR-375, miR-431, miR-433-3p, miR-433-5p, miR-434-3p, miR-434-5p |
 | Negative set | let-7 |
 |  | mir-276b, mir-278, mir-286, mir-287, mir-288, mir-303, mir-316, mir-317, mir-318 |
 |  | mir-124, miR-34, mir-375 |
 |  | let-7b, let-7e, miR-15, miR-16, miR-24, miR-103, miR-141, miR-145, miR-1, miR-19a, miR-34 | </md>


[User] <|image|>Parse the image content behind with markdown code: <md> |  | Number of broad reasons | Number of narrow reasons (for/against CO)

[Assistant]
| Number of reason mentions |
 | --- | --- | --- | --- |
 | Moral reasons | 11 | 58 (47/11) | 150 |
 | Practical reasons | 5 | 30 (14/16) | 52 |
 | Religious reasons | 4 | 15 (12/3) | 28 |
 | Legal reasons | 3 | 13 (8/5) | 39 |
 | Total | 23 | 116 (81/35) | 269 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> |  | <COLSPAN=2> Model 1 (n = 1125) | <COLSPAN=2> Model 2 (n = 1130) | <COLSPAN=2> Model 3 (n = 2069) |
 | Covariate | Beta-coefficient# | 95% CI | Beta-coefficient# | 95% CI |

[Assistant]
Beta-coefficient# | 95% CI |
 | --- | --- | --- | --- | --- | --- | --- |
 | Emergency surgery | 0.437 | –0.136, 1.010 | 0.547 | 0.025, 1.069* | 0.730 | 0.439, 1.020* |
 | Respiratory rate | 0.060 | 0.018, 0.102* | 0.005 | 0.002, 0.007* | 0.064 | 0.041, 0.087* |
 | Systolic blood pressure | –0.019 | –0.031, –0.008* | 0.002 | 0.001, 0.004* | 0.003 | –0.002, 0.008 |
 | Glasgow Coma Scale | –0.099 | –0.139, –0.059* | –0.150 | –0.185, –0.115* | –0.128 | –0.151, –0.105* |
 | Blood urea | 0.006 | 0.003, 0.008* | 0.006 | 0.004, 0.009* | NA | – |
 | Haemoglobin | –0.093 | –0.160, –0.027* | –0.098 | –0.161, –0.034* | NA | – |
 | Vasoactive use | 1.057 | 0.5613, 1.5527* | NA | – | NA | – |
 | Mechanical ventilation | 1.429 | 0.9919, 1.8661* | NA | – | NA | – |
 | Constant | 6.164 | 4.374, 7.953 | 0.588 | –0.358, 1.534 | 0.229 | –0.061, 0.518 | </md>


[User] <|image|>Parse the following content of the figure in markdown code: <md> |  | Ankylosauria | Ceratopsidae | Hadrosauridae (Q) | Hadrosauridae (B)

[Assistant]
|
 | --- | --- | --- | --- | --- |
 | Ankylosauria |  | 0.24 | 0.00 | 0.00 |
 | Ceratopsidae | 1 |  | 0.00 | 0.00 |
 | Hadrosauridae (Q) | 0.00 | 0.02 |  | 0.00 |
 | Hadrosauridae (B) | 0.00 | 0.02 | 0.00 |  | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Criteria |  | Score |
 | --- | --- | --- |
 | <ROWSPAN=3> Level of consciousness | Awake and oriented | 2 |
 | Arousable with minimal stimulation | 1 |
 | Responsive only to tactile stimulation | 0 |
 | <ROWSPAN=3> Physical activity | Able to move all extremities on command | 2 |
 | Some weakness in movement on extremities | 1 |
 | Unable to voluntarily move extremities | 0 |
 | <ROWSPAN=3> Hemodynamic stability | Blood pressure <15% of baseline MAP value | 2 |
 | Blood pressure 15–30% of baseline MAP value | 1 |
 | Blood pressure >30% below baseline MAP value | 0 |
 | <ROWSPAN=3> Respiratory stability | Able to breathe deeply | 2

[Assistant]
|
 | Tachypnea with good cough | 1 |
 | Dyspneic with weak cough | 0 |
 | <ROWSPAN=3> Oxygen saturation status | Maintains value >90% on room air | 2 |
 | Requires supplemental oxygen | 1 |
 | Saturation <90% with supplemental oxygen | 0 |
 | <ROWSPAN=3> Postoperative pain assessment | None or mild discomfort | 2 |
 | Moderate to severe pain controlled with IV analgesics | 1 |
 | Persistent severe pain | 0 |
 | <ROWSPAN=3> Postoperative emetic symptoms | None or mild nausea with no active vomiting | 2 |
 | Transient vomiting or retching | 1 |
 | Persistent moderate to severe nausea or vomiting | 0 |
 | Total score |  | 14 | </md>


[User] <|image|>Convert the illustration to Markdown syntax.

[Assistant]
<md> | Study variables | Total | RSOD at least once monthly (%) | p-valuesc |
 | --- | --- | --- | --- |
 | <COLSPAN=4> RSODa |
 | Never | 1079 (29.7) |  |  |
 | Less than monthly | 1628 (44.9) |  |  |
 | 1–3 times per month | 676 (18.6) |  |  |
 | At least 1–3 times per week | 247 (6.8) |  |  |
 | Female | 1958 (54.3) | 16.2 | < 0.001 |
 | Male |  | 36.6 |  |
 | Age |  |  | < 0.001 |
 | 26–35 | 621 (17.2) | 35.1 |  |
 | 36–45 | 907 (25.2) | 23.9 |  |
 | 46–55 | 1040 (28.8) | 25.6 |  |
 | 56+ | 1036 (28.8) | 21.0 |  |
 | Education, mean years of schooling (SD)b | 14.3 (2.94) |  | 0.635 |
 | Log income, mean (SD) | 5.5 (0.21) |  | < 0.001 |
 | <COLSPAN=4> Employment status |
 | Employed | 2534 (70.3) | 27.1 | < 0.001 |
 | Student/pupil | 105 (2.9) | 41.9 |  |
 | Unemployed | 108 (3.0) | 26.2 |  |
 | Pensioner | 595 (16.5) | 17.5 |  |
 | Other including homemakers | 266 (7.3) | 21.2 |  |
 | Civil status |  |  | < 0.001 |
 | In relationship | 2927 (81.2) | 24.0 |  |
 | Not in a relationship | 322 (9.0) | 26.7 |  |
 | Single | 354 (9.8) | 36.5 |  |
 | Living with children (<18 yr.) | 1499 (41.7) | 21.9 | < 0.001 |
 | Religiosityb | 597 (16.6) | 19.4 | < 0.001 |
 | Residence area |  |  | < 0.001 |
 | Capital | 699 (19.4) | 32.0 |  |
 | Rural | 1519 (42.2) | 21.6 |  |
 | Other cities | 1384 (38.4) | 26.0 |  | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Variable | n | Mean | Standard deviation | Minimum | Maximum |
 | --- | --- | --- | --- | --- | --- |
 | Population | 268 | 1,848,263 | 1,462,705 | 26,347 | 11,350,290 |
 | Area (km2) | 268 | 17,552 | 21,094 | 160 | 154,191 |
 | Population density (per km2) | 268 | 346 | 835 | 3 | 9142 |
 | PM10: population-weighted annual average (μg.m-3) | 268 | 22.3 | 7.6 | 2.7 | 48.5 |
 | PM10: population-weighted 36th highest daily mean (μg.m-3) | 268 | 37.1 | 13.1 | 3.4 | 82.7 |
 | Mean household income (PPCS) | 235 | 14,689 | 5,389 | 2,736 | 29,707 |
 | Mean smoking rate (%, country level) | 29 | 32.0 | 1.18 | 18.6 | 45.1 |
 | <COLSPAN=6> Premature mortality rate (per 100,000, 2004–2006) |
 | All-cause male | 210 | 305.3 | 124.2 | 103.2 | 706.6 |
 | All-cause female | 210 | 145.6 | 40.9 | 78.3 | 279.5 |
 | Circulatory disease male | 210 | 79.6 | 52.7 | 24.2 | 274.8 |
 | Circulatory disease female | 210 | 27.2 | 19.5 | 7.8 | 104.3 |
 | Respiratory disease male | 210 | 11.8 | 7.3 | 2.8 | 47.2 |
 |

[Assistant]
Respiratory disease female | 210 | 6.0 | 3.4 | 1.5 | 20.4 |
 | Chronic liver disease male | 210 | 16.5 | 12.9 | 1.8 | 80.6 |
 | Chronic liver disease female | 210 | 5.9 | 4.6 | 0.6 | 26.2 | </md>


[User] <|image|>Transcribe the photo into Markdown format.

[Assistant]
<md> | Site | Number of consent forms per site | Incidental finding strategies employed (see Table 4) per site |
 | --- | --- | --- |
 | Site 1 | 8 | A, B, M |
 | Site 2 | 5 | C |
 | Site 3 | 4 | D,E,F |
 | Site 4 | 10 | G, H, M |
 | Site 7 | 5 | I, K, M |
 | Site 9 | 7 | I, K, L, M | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> | Factor | OR (95 % CI) | OR adjusteda (95 % CI) |
 | --- | --- | --- |
 | Age >35 | 1.85 (1.35–2.53) | 2.50 (1.75–3.57) |
 | Male | 1.40 (0.96–2.04) | 1.78 (1.17–2.73) |
 | Bolivian origin | 7.52 (5.11–11.07) | 8.09 (5.44–12.03) |
 | Rural origin | 1.80 (1.27–2.57) | 1.62 (1.09–2.39) |
 | Less

[Assistant] than 5 years out of Latin America | 1.20 (0.88–1.63) | 1.39 (0.98–1.97) | </md>


[User] <|image|>Convert the table into Markdown language.

[Assistant]
<md> |  | EC FFPE primary tumor with no recurrence, N = 14 | EC FFPE primary tumor with recurrence, N = 7 | p-value |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Micro-RNA-184 |
 | FC < 0.083 | 3 (33%) | 6 (66%) | <ROWSPAN=2> 0.016 |
 | FC > 0.083 | 11 (92%) | 1 (8%) |
 | <COLSPAN=4> Micro-RNA-497-5p |
 | FC < 0.45 | 1 (20%) | 4 (80%) | <ROWSPAN=2> 0.025 |
 | FC > 0.45 | 13 (81%) | 3 (19%) |
 | <COLSPAN=4> Micro-RNA-195-5p |
 | FC < 0.58 | 1 (20%) | 4 (80%) | <ROWSPAN=2> 0.025 |
 | FC > 0.58 | 13 (81%) | 3 (19%) |
 | <COLSPAN=4> Micro-RNA-196-3p |
 | FC < 0.56 | 0 (0%) | 5 (100%) | <ROWSPAN=2> 0.001 |
 | FC > 0.56 | 14 (87%) | 2 (13%) | </md>


[User]
<|image|>What are the following image content in markdown style: <md> |  | <underline>NCI-60 – HuFL</underline> | <underline>Brc 8k – HuFL</underline> | <underline>Brc8k – U95Av2</underline> | <underline>Lung – U95Av2</underline> |
 | --- | --- | --- | --- | --- |
 | Total cDNA clones | 9707 | 8820 | 8820 | 22691 |
 | Clones with both reads sequenced | 6222 | 7015 | 7015 | 18645 |
 | Clones with predicted insert region | 4639 | 6354 | 6354 | 14813 |
 |

[Assistant]
Total Probe-sets defined | 1765 | 2403 | 3103 | 4597 |
 | Total (perfect match) probes on Affymetrix platform | 131541 | 131541 | 199084 | 199084 |
 | Total mapped probes | 26347 | 37559 | 48250 | 70001 |
 | Probes mapped to multiple clones | 904 | 3224 | 4019 | 26765 |
 | Number of probe-sets with > 1 Affymetrix "probe-set" represented | 115 | 310 | 664 | 888 | </md>


[User] <|image|>Encode the table in Markdown syntax.

[Assistant]
<md> | Treatment |  | Surgery | Brace | Controls |
 | --- | --- | --- | --- | --- |
 | Years follow-up |  | 23.3 | 22.3 |  |
 | Population |  | 146 | 116 | 100 |
 | Scoliosis | Start | 61.8 | 33.2 |  |
 |  | End of treatment | 33.1 | 29.7 |  |
 |  | Change from start | -53.6% | -89.5% |  |
 |  | Today | 36.5 | 37.6 |  |
 |  | Change from start | -59.1% | 12% |  |
 |  | Change from end | 9% | 21% |  |
 | Kyphosis | Today | 24.5 | 30.8 | 38.5 |
 | Lordosis | Today | 33.3 | 44.8 | 43.9 |
 | Hump | Measuring device | Bunnell | Bunnell |  |
 |  | Today | 11.4 | 10.3 |  | </md>